<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antiplatelet agents for the treatment of deep venous thrombosis - Flumignan, CDQ - 2022 | Cochrane Library</title> <meta content="Antiplatelet agents for the treatment of deep venous thrombosis - Flumignan, CDQ - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012369.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antiplatelet agents for the treatment of deep venous thrombosis - Flumignan, CDQ - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012369.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012369.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antiplatelet agents for the treatment of deep venous thrombosis" name="citation_title"/> <meta content="Carolina DQ Flumignan" name="citation_author"/> <meta content="carolina.flumignan@gmail.com" name="citation_author_email"/> <meta content="Luis CU Nakano" name="citation_author"/> <meta content="Jose CC Baptista-Silva" name="citation_author"/> <meta content="Ronald LG Flumignan" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD012369.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/07/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012369.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012369.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012369.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [adverse effects]; Hemorrhage [chemically induced]; Platelet Aggregation Inhibitors [adverse effects]; *Pulmonary Embolism [drug therapy, etiology]; *Venous Thromboembolism; *Venous Thrombosis [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012369.pub2&amp;doi=10.1002/14651858.CD012369.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ytRBD0EW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012369\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012369\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","pt","th","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012369.pub2",title:"Antiplatelet agents for the treatment of deep venous thrombosis",firstPublishedDate:"Jul 25, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012369.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012369.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012369.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012369.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012369.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012369.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012369.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012369.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012369.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012369.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6631 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012369.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-sec-0099"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-sec-0091"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/appendices#CD012369-sec-0104"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/table_n/CD012369StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/table_n/CD012369StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antiplatelet agents for the treatment of deep venous thrombosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/information#CD012369-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Carolina DQ Flumignan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/information#CD012369-cr-0005">Luis CU Nakano</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/information#CD012369-cr-0006">Jose CC Baptista-Silva</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012369.pub2/information#CD012369-cr-0007">Ronald LG Flumignan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/information/en#CD012369-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 July 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012369.pub2">https://doi.org/10.1002/14651858.CD012369.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012369-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012369-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012369-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012369-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012369-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012369-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD012369-abs-0007">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012369-abs-0001" lang="en"> <section id="CD012369-sec-0001"> <h3 class="title" id="CD012369-sec-0001">Background</h3> <p>Antiplatelet agents may be useful for the treatment of deep venous thrombosis (DVT) when used in addition to best medical practice (BMP), which includes anticoagulation, compression stockings, and clinical care such as physical exercise, skin hydration, etc. Antiplatelet agents could minimise complications such as post‐thrombotic syndrome (PTS) and pulmonary embolism (PE). They may also reduce the recurrence of the disease (recurrent venous thromboembolism (recurrent VTE)). However, antiplatelet agents may increase the likelihood of bleeding events. </p> </section> <section id="CD012369-sec-0002"> <h3 class="title" id="CD012369-sec-0002">Objectives</h3> <p>To assess the effects of antiplatelet agents in addition to current BMP compared to current BMP (with or without placebo) for the treatment of DVT. </p> </section> <section id="CD012369-sec-0003"> <h3 class="title" id="CD012369-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase and CINAHL databases and World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 7 December 2021. The review authors searched LILACS and IBECS databases (15 December 2021) and also checked the bibliographies of included trials for further references to relevant trials, and contacted specialists in the field, manufacturers and authors of the included trials. </p> </section> <section id="CD012369-sec-0004"> <h3 class="title" id="CD012369-sec-0004">Selection criteria</h3> <p>We considered randomised controlled trials (RCTs) examining antiplatelet agents compared to BMP following initial standard anticoagulation treatment for DVT. We included studies where antiplatelet agents were given in addition to current BMP compared to current BMP (with or without placebo) for the treatment of DVT (acute: treatment started within 21 days of symptom onset; chronic: treatment started after 21 days of symptom onset). We evaluated only RCTs where the antiplatelet agents were the unique difference between the groups (intervention and control). </p> </section> <section id="CD012369-sec-0005"> <h3 class="title" id="CD012369-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodological procedures. Two review authors independently extracted data and assessed risk of bias of the trials. Any disagreements were resolved by discussion with a third review author. We calculated outcome effects using risk ratio (RR) or mean difference (MD) with a 95% confidence interval (CI) and the number needed to treat to benefit (NNTB). </p> </section> <section id="CD012369-sec-0006"> <h3 class="title" id="CD012369-sec-0006">Main results</h3> <p>We included six studies with 1625 eligible participants, with data up to 37.2 months of follow‐up. For one preplanned comparison (i.e. antiplatelet agents plus BMP versus BMP plus placebo) for acute DVT we identified no eligible studies for inclusion. </p> <p>In acute DVT, antiplatelet agents plus BMP versus BMP alone was assessed by one study (500 participants), which reported on four outcomes until 6 months of follow‐up. There were no deaths and no cases of major bleeding reported. The participants who received antiplatelet agents showed a lower risk of PTS (RR 0.74, 95% CI 0.61 to 0.91; 1 study, 500 participants; very low‐certainty evidence). The control group presented a lower risk of adverse events compared to the intervention group (RR 2.88, 95% CI 1.06 to 7.80; 1 study, 500 participants; very low‐certainty evidence). This study did not provide information for recurrent VTE or PE. </p> <p>In chronic DVT, antiplatelet agents plus BMP versus BMP alone was assessed by one study (224 participants). The study authors reported four relevant outcomes, three of which (major bleeding, mortality and adverse events) showed no events during the 3 years of follow‐up. Therefore, an effect estimate could only be reported for recurrent VTE, favouring antiplatelet agents plus BMP versus BMP alone (RR 0.12, 95% CI 0.05 to 0.34; 1 study, 224 participants; very low‐certainty evidence). For the outcomes PE and PTS, this study did not present information which could be used for analysis. </p> <p>In chronic DVT, antiplatelet agents plus BMP versus BMP plus placebo was assessed by four studies (901 participants). The meta‐analysis of this pooled data showed a lower risk of recurrent VTE for the antiplatelet agents group (RR 0.65, 95%, CI 0.43 to 0.96; NNTB = 14; low‐certainty evidence). For major bleeding, we found no clear difference between placebo and intervention groups until 37.2 months of follow‐up (RR 0.98, 95% CI 0.29 to 3.34; 1 study, 583 participants; moderate‐certainty evidence). In PE fatal/non‐fatal outcome, we found no clear difference with the use of antiplatelet agents (RR 0.52, 95% CI 0.23 to 1.14; 1 study, 583 participants; moderate‐certainty evidence). For all‐cause mortality, the overall effect of antiplatelet agents did not differ from the placebo group (RR 0.48, 95% CI 0.21 to 1.06; 3 studies, 649 participants; moderate‐certainty evidence). The adverse events outcome did not show a clear difference (RR 1.57, 95% CI 0.34 to 7.19; 2 studies, 621 participants; moderate‐certainty evidence). There is no assessment of PTS in these studies. </p> <p>We downgraded the certainty of evidence for risk of bias, indirectness, imprecision and publication bias. </p> </section> <section id="CD012369-sec-0007"> <h3 class="title" id="CD012369-sec-0007">Authors' conclusions</h3> <p>In chronic DVT settings, following the initial standard treatment with anticoagulants, there is low‐certainty evidence that antiplatelet agents in addition to BMP may reduce recurrent VTE, (NNTB = 14) when compared to BMP plus placebo. Moderate‐certainty evidence shows no clear difference in adverse events, major bleeding and PE when antiplatelet agents are used in addition to BMP compared to BMP plus placebo. </p> <p>In acute and chronic DVT settings, following the initial standard treatment with anticoagulants, we can draw no conclusions for antiplatelet agents in addition to BMP compared to BMP alone due to very low‐certainty evidence.  </p> <p>Trials of high methodological quality, that are large and of sufficient duration to detect significant clinical outcomes are needed. Trials should ideally last more than 4 years in order to estimate the long‐term effect of antiplatelet agents. Trials should include people with acute and chronic DVT and provide relevant individual data, such as the outcome for each index event (DVT or PE), the use of an inferior vena cava (IVC) filter, whether the DVT is provoked or unprovoked, and the age of participants. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012369-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012369-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012369-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012369-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012369-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012369-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012369-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012369-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012369-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD012369-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012369-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012369-abs-0002" lang="en"> <h3>Aspirin and similar drugs for the treatment of deep vein thrombosis (DVT)</h3> <p><b>Key messages</b> </p> <p>‐ When used after standard initial treatment with anticoagulants, aspirin and similar drugs (antiplatelet agents) in addition to best medical practice (BMP), may reduce recurrent venous thromboembolism (VTE), i.e. deep vein thrombosis (DVT) or pulmonary embolism (PE), when compared to BMP plus placebo in a chronic DVT setting. There is no clear difference in side effects, major bleeding or PE with the use of antiplatelet agents. </p> <p>‐ Studies of high methodological quality that are large and long enough to detect significant clinical outcomes are needed to assess the long‐term effect of antiplatelet agents. Studies should include people with acute and chronic DVT and include information about important outcomes such as DVT, PE and major bleeding, the use of an inferior vena cava (IVC) filter, and the age of the participants. </p> <p><b>What is DVT?</b> </p> <p>DVT is a blood clot formed inside the venous system of the body, blocking the flow of blood. </p> <p><b>How is DVT treated?</b> </p> <p>After initial treatment with anticoagulants, people receive follow‐up treatment (known as BMP) which include drugs for preventing new clots, compression stockings and clinical care (such as physical exercise and skin hydration). Antiplatelets such as aspirin, are medicines that stop cells in the blood (platelets) from sticking together and forming a clot. They could therefore be seen as a potential additional intervention to the current BMP for treating DVT. Antiplatelets could be used to minimise complications such as post‐thrombotic syndrome (PTS, a situation in which a blood clot in the vein causes impaired function in the affected vessels), and PE (when the blood clot travels through the bloodstream to the lung and blocks its flow). Antiplatelets may also reduce the recurrence of DVT or PE. One drawback of the use of antiplatelets is the potential for an increase in bleeding. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know whether giving antiplatelets to people to treat DVT, following initial treatment, reduced the number of recurrent VTEs, bleeding or PE compared to people who received only BMP or BMP plus placebo (an identical‐seeming treatment but with no medical effect). We also wanted to determine whether antiplatelets reduced death, whether people developed PTS, whether they experienced side effects, whether their quality of life improved and whether there was a change in the length of time spent in hospital. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that assessed antiplatelets given to people to treat DVT. Studies should have a randomised design (when participants are randomly allocated to treatment groups) as long as they compared an antiplatelet plus BMP with BMP alone or BMP with placebo. These treatments were started after initial standard anticoagulation for DVT. We pooled the results when appropriate. </p> <p><b>What did we find?</b> </p> <p>The results are based on six studies with 1625 participants from the USA, Canada, Europe, India, Argentina, Australia and New Zealand. Two large groups of participants were studied: participants with acute DVT (treatment started up to 21 days after symptoms), and participants with chronic DVT (treatment started after 21 days of symptoms). All studies used BMP as a comparison, or BMP plus placebo. Each comparison investigated the effects of antiplatelets on the recurrence of DVT, PE, death and side effects. </p> <p>We have limited confidence that antiplatelets in addition to BMP may have an effect on reducing the risk of a new episode of VTE when compared to BMP with placebo in a chronic DVT setting. It is necessary to treat 14 patients to avoid one VTE event. When only PE was studied, however, antiplatelets did not achieve a difference between the groups. The use of antiplatelets as an additional treatment does not appear to add any harm or risks, such as death, bleeding, or other side effects. </p> <p>Although our confidence in the evidence is very limited, people who receive antiplatelets may have lower rates of recurrent VTE compared to those who did not receive antiplatelets in a chronic DVT setting. Similarly, although our confidence in the evidence is very limited, people who receive antiplatelets may have a lower rate of PTS and increased side effects in an acute DVT setting. </p> <p>We can draw no conclusions from the very limited available evidence for using antiplatelets as an additional treatment to BMP compared with BMP alone in acute and chronic DVT settings. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence was limited or very limited because few people experienced the outcomes, and some studies' limitations could introduce errors, for example randomisation and selective reporting concerns, poorly‐defined outcomes and duplicate publication. </p> <p>Future high‐quality studies may produce important data, especially for results such as death and side effects, as well as the treatment of acute DVT. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up to date to 7 December 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012369-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012369-sec-0099"></div> <h3 class="title" id="CD012369-sec-0100">Implications for practice</h3> <section id="CD012369-sec-0100"> <p>Low‐certainty evidence (4 RCTs, 901 participants) suggests that antiplatelet agents in addition to BMP compared to BMP plus placebo for the treatment of chronic DVT, following the standard initial treatment with anticoagulants, may reduce the risk of recurrent VTE (NNTB = 14) from 3 months to 37.2 months of follow‐up. Moderate‐certainty evidence suggests there is no additional risk of major bleeding, mortality, PE or adverse events in the same setting. </p> <p>It is uncertain whether antiplatelet agents in addition to BMP in chronic DVT, when compared to BMP without a placebo control, reduce the risk of recurrent VTE or result in additional risks, such as major bleeding, mortality and any adverse events (very low‐certainty evidence). </p> <p>It is uncertain if antiplatelet agents in addition to BMP, when compared to BMP alone, for the treatment of acute DVT may reduce the risk of PTS but increase the risk of adverse events until 6 months of follow‐up (very low‐certainty evidence). These results should be viewed with caution because none of the primary outcomes (VTE, PE and major bleeding) had estimable data in acute DVT. In addition, PTS was evaluated only at 6 months of follow‐up and data on intermediate, and long‐term outcomes could bring about substantial differences in the results. </p> <p>Therefore, following initial standard anticoagulation, use of antiplatelet agents in addition to BMP for the treatment of chronic DVT may have some benefits in reducing the risk of recurrent VTE without harm and the risk of mortality, major bleeding and adverse events. However, new high‐certainty evidence may add some important information, especially regarding outcomes without available data (QoL) or estimable effects (major bleeding, mortality, PE and adverse events). </p> </section> <h3 class="title" id="CD012369-sec-0101">Implications for research</h3> <section id="CD012369-sec-0101"> <p>The majority of included studies in our review are small trials and this type of review has been described as important by others (<a href="./references#CD012369-bbs2-0042" title="HandollHH , LanghorneP . In defence of reviews of small trials: underpinning the generation of evidence to inform practice. Cochrane Database of Systematic Reviews2015;(11). [DOI: 10.1002/14651858.ED000106]">Handoll 2015</a>). However, our review has limitations such as the possibility of publication bias, the very selective inclusion criteria in the primary studies and a very small number of less frequent events (e.g. PE, mortality and adverse events). Future trials need to be large enough to detect significant clinical outcomes, include all main clinical outcomes (recurrent VTE, PE and major bleeding), report the outcomes separately for different populations (e.g. with confirmed DVT and with only PE) and should ideally last more than 4 years to estimate the long‐term effects of antiplatelet agents. This minimum follow‐up time of 4 years is arbitrary, but it would produce additional data about rare occurrences, such as adverse events following antiplatelet agents, and could highlight the effects on chronic morbidity, such as PTS and QoL. Future trials on VTE should include participants with acute and chronic DVT and PE. Investigators should also provide the outcomes by the index event (DVT and/or PE) and not only for the general population of VTE. Continuous data need to be uniform, using similar scales/scores (especially for PTS and QoL evaluations), or transformed into dichotomous data when at all possible. The control groups should use a placebo in the same posology of the intervention group to avoid the lack of blinding. Since placebo control is feasible and it improves the methodological quality of the study, in the future we hope to find only new RCTs with placebo or other active drug control. </p> <p>Also, it might be useful to differentiate the effects of antiplatelet agents on younger and older participants, the specific thrombosis level, and whether the DVT was provoked or unprovoked. The use of an IVC filter is also a potential confounder and should be reported. A Cochrane Review assessed DOACs for DVT treatment by demonstrating reduced bleeding when compared to warfarin (<a href="./references#CD012369-bbs2-0063" title="RobertsonL , KestevenP , McCaslinJE . Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews2015, Issue 6. Art. No: CD010956. [DOI: 10.1002/14651858.CD010956.pub2]">Robertson 2015</a>). Therefore, future RCTs should also be subgrouped by anticoagulant type for better interpretation of the results. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012369-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012369-sec-0008"></div> <div class="table" id="CD012369-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Acute DVT ‐ antiplatelet agents plus BMP compared to BMP alone for the treatment of DVT</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antiplatelet agents plus BMP compared to BMP alone for the treatment of acute DVT</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring treatment for acute DVT<br/><b>Setting:</b> outpatient setting<br/><b>Intervention:</b> antiplatelet agents plus BMP<br/><b>Comparison:</b> BMP alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with BMP alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antiplatelet agents plus BMP</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b><br/>follow‐up: range 3 months to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported on a 6‐point scale used for clinical and ultrasonic assessment of efficacy, which included, among other outcomes, embolisation. Components of the score were not reported separately. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported no major bleeding.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pulmonary embolism</b><br/>follow‐up: range 3 months to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported on a 6‐point scale used for clinical and ultrasonic assessment of efficacy, which included, among other outcomes, embolisation. Components of the score were not reported separately. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> ‐ early and intermediate </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported no deaths.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Post‐thrombotic syndrome</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/>(0.61 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>580 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>151 less per 1000<br/>(226 less to 52 less) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.88<br/>(1.06 to 7.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 more per 1000<br/>(2 more to 272 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMP:</b> best medical practice; <b>CI:</b> confidence interval; <b>DVT:</b> deep venous thrombosis; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded a half level due to imprecision: fewer than 300 events were included in the analysis.<br/><sup>b</sup>Downgraded two levels due to study limitations. Despite the study described as blinded, the study did not have a control group with placebo, and intervention groups had differences in the number of tablets per day. Losses and exclusion were not mentioned. Some of the study's prespecified outcomes (such as embolisation) that were of interest for this review have not been reported. The full protocol was not available, only information in the study report. There was suspicion of pharmaceutical company support, although not clearly mentioned in the study report.<br/><sup>c</sup>Downgraded one level due to indirectness: there was no explanation about what was considered major bleeding.<br/><sup>d</sup>Downgraded a half level due to indirectness: the study authors did not utilise a validated method to assess post‐thrombotic syndrome. Only subjective vision of the participant. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012369-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Chronic DVT ‐ antiplatelet agents plus BMP compared to BMP alone for the treatment of DVT</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antiplatelet agents plus BMP compared to BMP alone for the treatment of chronic DVT</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring treatment for chronic DVT<br/><b>Setting:</b> outpatient setting<br/><b>Intervention:</b> antiplatelet agents plus BMP<br/><b>Comparison:</b> BMP alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with BMP alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antiplatelet agents plus BMP</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b> ‐ early and intermediate </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.12<br/>(0.05 to 0.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>224<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Includes recurrent DVT only</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>293 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>258 less per 1000<br/>(278 less to 193 less) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>224<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported no major bleeding.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pulmonary embolism</b><br/>follow‐up: range 1 year to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>224<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported no pulmonary embolism.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> ‐ early and intermediate </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>224<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported no deaths.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Post‐thrombotic syndrome</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies measured this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>224<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported no adverse events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMP:</b> best medical practice; <b>CI:</b> confidence interval; <b>DVT:</b> deep venous thrombosis; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded a half level due to imprecision: fewer than 300 events were included in the analysis.<br/><sup>b</sup>Downgraded two levels due to study limitations: the control group did not have an oral treatment, not even placebo; participants and personnel were not blinded; authors reported that all included participants concluded the analysis but there were dropouts in all groups, without details provided; the full protocol was not available, only report information.<br/><sup>c</sup>Downgraded one level due to other considerations: there is suspicion of duplicate publication.<br/><sup>d</sup>Downgraded one level due to indirectness: no explanation as to what was considered major bleeding or if there was any. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012369-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Chronic DVT ‐ antiplatelet agents plus BMP compared to BMP plus placebo for the treatment of DVT</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antiplatelet agents plus BMP compared to BMP plus placebo for the treatment of chronic DVT</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring treatment for chronic DVT<br/><b>Setting:</b> outpatient setting<br/><b>Intervention:</b> antiplatelet agents plus BMP<br/><b>Comparison:</b> BMP plus placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with BMP plus placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antiplatelet agents plus BMP</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b> ‐ early, intermediate and long term </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.65 (0.43 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>901</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>206 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 less per 1000 (118 less to 8 less)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.29 to 3.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>583<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two studies did not assess this outcome (<a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>) and for one study the data were not available for our population of interest (<a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>). Only <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> had data for the analysis. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(12 less to 41 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pulmonary embolism</b> (fatal/non‐fatal) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.52<br/>(0.23 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>583<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two studies did not assess this outcome (<a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>) and for one study the data were not available for our population of interest (<a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>). Only <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> had data for the analysis. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 less per 1000<br/>(45 less to 8 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> ‐ intermediate and long term </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/>(0.21 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>649<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 less per 1000<br/>(42 less to 3 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Post‐thrombotic syndrome</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies measured this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.57<br/>(0.34 to 7.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>621<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 more per 1000<br/>(49 less to 464 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMP:</b> best medical practice; <b>CI:</b> confidence interval; <b>DVT:</b> deep venous thrombosis; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded a half level due to imprecision: fewer than 300 events were included in the analysis.<br/><sup>b</sup>Downgraded a half level due to study limitations: in the <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> protocol, we identified a change in primary and secondary outcomes during the study. <br/><sup>c</sup>Downgraded a half level due to study limitations: the <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> study included one group treated with warfarin, after randomisation. Moreover, the investigators used different anticoagulation treatments (warfarin or heparin) for some participants, and this was not sufficiently described. There are no details of numbers of anticoagulated participants in each group. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012369-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012369-sec-0009"></div> <p>See <a href="./appendices#CD012369-sec-0105">Appendix 1</a> for a glossary of terms. </p> <section id="CD012369-sec-0010"> <h3 class="title" id="CD012369-sec-0010">Description of the condition</h3> <p>Venous thromboembolism (VTE) describes the formation of a thrombus (blood clot) in the deep veins, most commonly in the legs (deep venous thrombosis or DVT) or the subsequent embolisation of all or part of the thrombus in the pulmonary circulation (pulmonary embolism or PE), or both. DVT is caused by the acute formation of a thrombus in veins situated under the muscular fascia of the limbs or in the deep central veins. In general, DVT situated between the popliteal vein and the iliac and inferior cava veins is designated a proximal DVT (<a href="./references#CD012369-bbs2-0084" title="VedanthamS , GrassiCJ , FerralH , PatelNH , ThorpePE , AntonacciVP , et al. Reporting standards for endovascular treatment of lower extremity deep vein thrombosis. Journal of Vascular and Interventional Radiology2009;20(7 Suppl):S391-408. [PMID: 19560027]">Vedantham 2009</a>). The clinical signs may vary depending on the extent of the clot and which veins are affected, but include localised pain, swelling and erythaema. Although DVT may cause discomfort, of utmost importance are the complications of this disorder: PE in the short term and post‐thrombotic syndrome (PTS) in the long‐term (<a href="./references#CD012369-bbs2-0017" title="ÁvilaRB , MarcondesGB , DiasSV , SilveiraBP , AmorimJE , GuedesHJ , et al. External validation of Villalta score in high-middle income country patients with deep vein thrombosis. Medicine2022;101(24):e29367. [DOI: 10.1097/MD.0000000000029367]">Avila 2022</a>; <a href="./references#CD012369-bbs2-0025" title="BroderickC , WatsonL , ArmonMP . Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb. Cochrane Database of Systematic Reviews2021, Issue 1. Art. No: CD002783. [DOI: 10.1002/14651858.CD002783.pub5]">Broderick 2021</a>; <a href="./references#CD012369-bbs2-0034" title="FlumignanRL , FlumignanCD , Baptista-SilvaJC . Angioplasty for deep venous thrombosis. Cochrane Database of Systematic Reviews2015, Issue 1. Art. No: CD011468. [DOI: 10.1002/14651858.CD011468]">Flumignan 2015</a>). PE occurs when a thrombus breaks away in the limb and follows the bloodstream to the lungs, blocking the circulation in part of the lung tissue. At least one‐third and sometimes one‐half of people with VTE develop PTS due to the damage to the vessel wall. PTS comprises a wide variety of symptoms ranging from relatively light symptoms (slight oedema, venous eczema, pigmentation and minor complaints) to more severe symptoms (severe swelling, venous claudication, pain and chronic recurrent ulcers). PTS can develop after DVT at any time, but mainly during the two years following diagnosis of DVT (<a href="./references#CD012369-bbs2-0017" title="ÁvilaRB , MarcondesGB , DiasSV , SilveiraBP , AmorimJE , GuedesHJ , et al. External validation of Villalta score in high-middle income country patients with deep vein thrombosis. Medicine2022;101(24):e29367. [DOI: 10.1097/MD.0000000000029367]">Avila 2022</a>; <a href="./references#CD012369-bbs2-0041" title="GuanellaR . Post-thrombotic syndrome: the forgotten complication of venous thromboembolism [Syndrome post-thrombotique: la complication negligee de la maladie thromboembolique veineuse]. Revue Médicale Suisse2013;9(372):321-5. [PMID: 23469400]">Guanella 2013</a>). The incidence of recurrent DVT in the PTS population is between 20% and 50% (<a href="./references#CD012369-bbs2-0017" title="ÁvilaRB , MarcondesGB , DiasSV , SilveiraBP , AmorimJE , GuedesHJ , et al. External validation of Villalta score in high-middle income country patients with deep vein thrombosis. Medicine2022;101(24):e29367. [DOI: 10.1097/MD.0000000000029367]">Avila 2022</a>; <a href="./references#CD012369-bbs2-0030" title="deWolfMA , WittensCH , KahnSR . Incidence and risk factors of the post-thrombotic syndrome. Phlebology/Venous Forum of the Royal Society of Medicine2012;27 Suppl 1:85-94. [PMID: 22312073]">de Wolf 2012</a>; <a href="./references#CD012369-bbs2-0041" title="GuanellaR . Post-thrombotic syndrome: the forgotten complication of venous thromboembolism [Syndrome post-thrombotique: la complication negligee de la maladie thromboembolique veineuse]. Revue Médicale Suisse2013;9(372):321-5. [PMID: 23469400]">Guanella 2013</a>). </p> <p>After stroke and myocardial infarction, VTE is the third most common cardiovascular disease in the world (<a href="./references#CD012369-bbs2-0037" title="GoldhaberSZ . Venous thromboembolism: epidemiology and magnitude of the problem. Best Practice and Research. Clinical Haematology2012;25(3):235-42. [PMID: 22959540]">Goldhaber 2012</a>; <a href="./references#CD012369-bbs2-0048" title="ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Thrombosis and Haemostasis2014;112(5):843-52. [PMID: 25300294]">ISTH 2014</a>). In the USA and Europe, an estimated 50,000 deaths and 300,000 hospitalisations per year are due to DVT, and 600,000 hospitalisations to PE (<a href="./references#CD012369-bbs2-0060" title="NicolaidesAN , BreddinHK , FareedJ , GoldhaberS , HaasS , HullR , et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. International Angiology2001;20(1):1-37. [PMID: 11342993]">Nicolaides 2001</a>). The incidence of DVT is growing with the ageing population, and the estimated rates vary from 1 to 2 per 1000 people per year, with approximately 100,000 to 180,000 deaths per year due to PE (<a href="./references#CD012369-bbs2-0036" title="GalanaudJP , KahnSR , Khau Van KienA , LarocheJP , QuereI . Epidemiology and management of isolated distal deep venous thrombosis [Thromboses veineuses profondes distales isolees des membres inferieurs: epidemiologie et prise en charge]. La Revue de Médecine Interne/fondee par la Societé nationale Française de Médecine Interne2012;33(12):678-85. [PMID: 22705030]">Galanaud 2012</a>; <a href="./references#CD012369-bbs2-0037" title="GoldhaberSZ . Venous thromboembolism: epidemiology and magnitude of the problem. Best Practice and Research. Clinical Haematology2012;25(3):235-42. [PMID: 22959540]">Goldhaber 2012</a>; <a href="./references#CD012369-bbs2-0054" title="MatieloMF , PrestiC , CasellaIB , NettoBM , Puech-LeaoP . Incidence of ipsilateral postoperative deep venous thrombosis in the amputated lower extremity of patients with peripheral obstructive arterial disease. Journal of Vascular Surgery2008;48(6):1514-9. [PMID: 18829221]">Matielo 2008</a>; <a href="./references#CD012369-bbs2-0058" title="NaessIA , ChristiansenSC , RomundstadP , CannegieterSC , RosendaalFR , HammerstromJ . Incidence and mortality of venous thrombosis: a population-based study. Journal of Thrombosis and Haemostasis2007;5(4):692-9. [PMID: 17367492]">Naess 2007</a>; <a href="./references#CD012369-bbs2-0080" title="TagalakisV , PatenaudeV , KahnSR , SuissaS . Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE study cohort. American Journal of Medicine2013;126(9):832.e13-21. [PMID: 23830539]">Tagalakis 2013</a>). Chronic cardiovascular diseases continue to be a major cause of health loss for all regions of the world, and VTE is one of the 10 leading causes of death (<a href="./references#CD012369-bbs2-0067" title="RothGA , JohnsonC , AbajobirA , Abd-AllahF , AberaSF , AbyuG , et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. Journal of the American College of Cardiology2017;70(1):1-25. [PMID: 28527533]">Roth 2017</a>). </p> <p>DVT is a multifactorial disease in which genetic and environmental factors interact with each other, leading to the onset of the disease (<a href="./references#CD012369-bbs2-0065" title="RosendaalFR . Venous thrombosis: the role of genes, environment, and behavior. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program2005;2005(1):1-12. [PMID: 16304352]">Rosendaal 2005</a>). Risk factors for DVT include older age (<a href="./references#CD012369-bbs2-0014" title="Anderson FA Jr, WheelerHB , GoldbergRJ , HosmerDW , PatwardhanNA , JovanovicB , et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Archives of Internal Medicine1991;151(5):933-8. [PMID: 2025141]">Anderson 1991</a>), immobilisation (<a href="./references#CD012369-bbs2-0075" title="SevittS , GallagherN . Venous thrombosis and pulmonary embolism. A clinico-pathological study in injured and burned patients. British Journal of Surgery1961;48:475-89. [PMID: 13750445]">Sevitt 1961</a>), previous VTE (<a href="./references#CD012369-bbs2-0068" title="SamamaMM . An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Archives of Internal Medicine2000;160(22):3415-20. [PMID: 11112234]">Samama 2000</a>), obesity (<a href="./references#CD012369-bbs2-0081" title="TsaiAW , CushmanM , RosamondWD , HeckbertSR , PolakJF , FolsomAR . Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Archives of Internal Medicine2002;162(10):1182-9. [PMID: 12020191]">Tsai 2002</a>), type of anaesthesia (<a href="./references#CD012369-bbs2-0083" title="UrwinSC , ParkerMJ , GriffithsR . General versus regional anaesthesia for hip fracture surgery: a meta-analysis of randomized trials. British Journal of Anaesthesia2000;84(4):450-5. [PMID: 10823094]">Urwin 2000</a>), cancer (<a href="./references#CD012369-bbs2-0043" title="HeitJA , SilversteinMD , MohrDN , PettersonTM , O'FallonWM , Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Archives of Internal Medicine2000;160(6):809-15. [PMID: 10737280]">Heit 2000</a>), chemotherapy (<a href="./references#CD012369-bbs2-0033" title="FalangaA , RicklesFR . Pathophysiology of the thrombophilic state in the cancer patient. Seminars in Thrombosis and Hemostasis1999;25(2):173-82. [PMID: 10357085]">Falanga 1999</a>), pregnancy and delivery (<a href="./references#CD012369-bbs2-0056" title="McCollMD , RamsayJE , TaitRC , WalkerID , McCallF , ConkieJA , et al. Risk factors for pregnancy associated venous thromboembolism. Thrombosis and Haemostasis1997;78(4):1183-8. [PMID: 9364982]">McColl 1997</a>), hormonal contraceptives (<a href="./references#CD012369-bbs2-0038" title="GomesMP , DeitcherSR . Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Archives of Internal Medicine2004;164(18):1965-76. [PMID: 15477430]">Gomes 2004</a>), hormone replacement (<a href="./references#CD012369-bbs2-0066" title="RossouwJE , AndersonGL , PrenticeRL , LaCroixAZ , KooperbergC , StefanickML , et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA2002;288(3):321-33. [PMID: 12117397]">Rossouw 2002</a>), and infection by the SARS‐CoV‐2 virus (<a href="./references#CD012369-bbs2-0028" title="COVIDSurg Collaborative, GlobalSurg Collaborative. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. Anaesthesia2022;77(1):28-39. [PMID: 10.1111/anae.15563]">COVIDSurg 2022</a>; <a href="./references#CD012369-bbs2-0035" title="FlumignanRL , CivileVT , TinôcoJD , PascoalPI , AreiasLL , MatarCF , et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD013739. [DOI: 10.1002/14651858.CD013739.pub2]">Flumignan 2022</a>; <a href="./references#CD012369-bbs2-0069" title="SantosBC , FlumignanRL , CivileVT , AtallahAN , NakanoLC . Prophylactic anticoagulants for non-hospitalised people with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015102. [DOI: 10.1002/14651858.CD015102]">Santos 2022</a>). </p> <p>Anticoagulants are the standard mode of treatment for DVT (<a href="./references#CD012369-bbs2-0028" title="COVIDSurg Collaborative, GlobalSurg Collaborative. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. Anaesthesia2022;77(1):28-39. [PMID: 10.1111/anae.15563]">COVIDSurg 2022</a>; <a href="./references#CD012369-bbs2-0035" title="FlumignanRL , CivileVT , TinôcoJD , PascoalPI , AreiasLL , MatarCF , et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD013739. [DOI: 10.1002/14651858.CD013739.pub2]">Flumignan 2022</a>; <a href="./references#CD012369-bbs2-0049" title="KakkosSK , GohelM , BaekgaardN , BauersachsR , Bellmunt-MontoyaS , BlackSA , et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the management of venous thrombosis. European Journal of Vacular and Endovascular Surgery2021;61(1):9-82. [PMID: 10.1016/j.ejvs.2020.09.023]">Kakkos 2021</a>; <a href="./references#CD012369-bbs2-0069" title="SantosBC , FlumignanRL , CivileVT , AtallahAN , NakanoLC . Prophylactic anticoagulants for non-hospitalised people with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015102. [DOI: 10.1002/14651858.CD015102]">Santos 2022</a>; <a href="./references#CD012369-bbs2-0079" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [DOI: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>). These drugs reduce the formation of clots and prevent further VTE. Other options for additional treatment of DVT include thrombolysis, mechanical thrombectomy, angioplasty and stenting (<a href="./references#CD012369-bbs2-0025" title="BroderickC , WatsonL , ArmonMP . Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb. Cochrane Database of Systematic Reviews2021, Issue 1. Art. No: CD002783. [DOI: 10.1002/14651858.CD002783.pub5]">Broderick 2021</a>; <a href="./references#CD012369-bbs2-0034" title="FlumignanRL , FlumignanCD , Baptista-SilvaJC . Angioplasty for deep venous thrombosis. Cochrane Database of Systematic Reviews2015, Issue 1. Art. No: CD011468. [DOI: 10.1002/14651858.CD011468]">Flumignan 2015</a>; <a href="./references#CD012369-bbs2-0064" title="RobertsonL , McBrideO , BurdessA . Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD011536. [DOI: 10.1002/14651858.CD011536.pub2]">Robertson 2016</a>). After initial treatments, follow‐on treatments including further anticoagulation, compression stockings and clinical care, such as physical exercises, skin hydration, etc. are implemented as per BMP for individual clinical settings (<a href="./references#CD012369-bbs2-0017" title="ÁvilaRB , MarcondesGB , DiasSV , SilveiraBP , AmorimJE , GuedesHJ , et al. External validation of Villalta score in high-middle income country patients with deep vein thrombosis. Medicine2022;101(24):e29367. [DOI: 10.1097/MD.0000000000029367]">Avila 2022</a>; <a href="./references#CD012369-bbs2-0028" title="COVIDSurg Collaborative, GlobalSurg Collaborative. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. Anaesthesia2022;77(1):28-39. [PMID: 10.1111/anae.15563]">COVIDSurg 2022</a>; <a href="./references#CD012369-bbs2-0035" title="FlumignanRL , CivileVT , TinôcoJD , PascoalPI , AreiasLL , MatarCF , et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD013739. [DOI: 10.1002/14651858.CD013739.pub2]">Flumignan 2022</a>; <a href="./references#CD012369-bbs2-0049" title="KakkosSK , GohelM , BaekgaardN , BauersachsR , Bellmunt-MontoyaS , BlackSA , et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the management of venous thrombosis. European Journal of Vacular and Endovascular Surgery2021;61(1):9-82. [PMID: 10.1016/j.ejvs.2020.09.023]">Kakkos 2021</a>; <a href="./references#CD012369-bbs2-0069" title="SantosBC , FlumignanRL , CivileVT , AtallahAN , NakanoLC . Prophylactic anticoagulants for non-hospitalised people with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015102. [DOI: 10.1002/14651858.CD015102]">Santos 2022</a>; <a href="./references#CD012369-bbs2-0079" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [DOI: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>). </p> </section> <section id="CD012369-sec-0011"> <h3 class="title" id="CD012369-sec-0011">Description of the intervention</h3> <p>Antiplatelet agents are drugs commonly used to decrease platelet aggregation and inhibit thrombus formation. Various antiplatelet agents are available, such as acetylsalicylic acid (ASA; aspirin), clopidogrel, phosphodiesterase inhibitors (dipyridamole and cilostazol) and glycoprotein IIb/IIIa inhibitors (tirofiban and abciximab). </p> <p>Antiplatelet agents, mostly ASA, are already routinely used in clinical practice to treat various cardiovascular problems. The routine use of ASA has already been established in cases of arterial thrombosis with a cardiac, cerebrovascular or peripheral origin. In coronary artery disease, ASA is part of the routine management of a wide spectrum of patients with coronary artery disease (<a href="./references#CD012369-bbs2-0023" title="BraunwaldE . The rise of cardiovascular medicine. European Heart Journal2012;33(7):838-45, 845a. [PMID: 22416074]">Braunwald 2012</a>). Clinical and experimental evidence suggests that antiplatelet agents can prevent the onset and spread of venous thrombus, minimising the adverse consequences of PE and DVT (<a href="./references#CD012369-bbs2-0027" title="CastroHC , FerreiraBL , NagashimaT , SchuelerA , RueffC , CamisascaD , et al. Platelets: still a therapeutical target [Plaquetas: ainda um alvo terapêutico]. Jornal Brasileiro de Patologia e Medicina Laboratorial2006;42(5):321-32. [DOI: 10.1590/S1676-24442006000500004]">Castro 2006</a>). In one multicentre, double‐blind study, over 400 people with a first unprovoked VTE who had completed six to 18 months of anticoagulation, were randomised to ASA or placebo. The study found a statistically significant difference in the reduction of recurrent VTE with ASA after discontinuing anticoagulation (<a href="./references#CD012369-bbs2-0018" title="BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]">Becattini 2012</a>). <a href="./references#CD012369-bbs2-0024" title="BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]">Brighton 2012</a> used a similar protocol (ASA after the end of anticoagulation therapy) and found no significant reduction in the rate of VTE recurrence, but did find a reduction in the rate of major vascular events. Similar to treatment with anticoagulants, antiplatelet therapy may require monitoring of blood tests, mainly due to the high incidence of resistance to ASA and clopidogrel, as well as resistance to glycoprotein IIb/IIIa (<a href="./references#CD012369-bbs2-0022" title="BrarSS , ten BergJ , MarcucciR , PriceMJ , ValgimigliM , KimHS , et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. Journal of the American College of Cardiology2011;58(19):1945-54. [PMID: 22032704]">Brar 2011</a>; <a href="./references#CD012369-bbs2-0031" title="El-AtatF , SarkarK , KodaliV , KarajgikarR , JakkullaM , MaresA , et al. A randomized pilot trial for aggressive therapeutic approaches in aspirin-resistant patients undergoing percutaneous coronary intervention. Journal of Invasive Cardiology2011;23(1):9-13. [PMID: 21183763]">El‐Atat 2011</a>; <a href="./references#CD012369-bbs2-0052" title="LugoJJ , HurtadoEF , CalderónLI , GómezG , CastroP , EstradaG , et al. Resistance to acetylsalicylic acid and to clopidogrel: an emergent clinical entity [Resistencia al ácido acetil salicílico y al clopidogrel: una entidad clínica emergente]. Revista Colombiana de Cardiología2008;15(4):172-83.">Lugo 2008</a>; <a href="./references#CD012369-bbs2-0055" title="MatzdorffA . Platelet function tests and flow cytometry to monitor antiplatelet therapy. Seminars in Thrombosis and Hemostasis2005;31(4):393-9. [PMID: 16149015]">Matzdorff 2005</a>). However, monitoring blood tests for antiplatelet agents are not routinely available in most practices. </p> </section> <section id="CD012369-sec-0012"> <h3 class="title" id="CD012369-sec-0012">How the intervention might work</h3> <p>Platelets are unique to mammals and are the principal effector cells on haemostasis, coagulation and thrombosis. They are a large part of the ‘haemostatic plug’, a combination of platelets and proteins that adheres to the site of vascular lesions. The secretion of von Willebrand factor by the damaged cells of the endothelium and other mediators of thrombosis from intracellular granules lead to the amplification of platelet adhesion and its aggregation. This receptor‐mediated activation event has been intensely studied because it is a fundamental part of the physiopathology of several diseases, including DVT (<a href="./references#CD012369-bbs2-0085" title="Vieira-de-AbreuA , CampbellRA , WeyrichAS , ZimmermanGA . Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Seminars in Immunopathology2012;34(1):5-30. [PMID: 21818701]">Vieira‐de‐Abreu 2012</a>). </p> <p>ASA inhibits platelet aggregation by arachidonic acid metabolism through inactivation of the enzyme cyclooxygenase, which is an irreversible event during the life of the platelet. Other antiplatelet agents, such as clopidogrel have different mechanisms of action. Clopidogrel is a thienopyridine and is chemically and pharmacologically similar to ticlopidine, which acts by selectively and irreversibly modifying the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface, thus inhibiting platelet aggregation. ADP is an important activator of platelet aggregation and is found in high concentrations in the platelet granules. ADP induces platelet aggregation by activating a specific receptor located on the outer surface of its membrane, which results in changes in intracellular calcium concentration and the expression of receptors for fibrinogen on the platelet surface (<a href="./references#CD012369-bbs2-0052" title="LugoJJ , HurtadoEF , CalderónLI , GómezG , CastroP , EstradaG , et al. Resistance to acetylsalicylic acid and to clopidogrel: an emergent clinical entity [Resistencia al ácido acetil salicílico y al clopidogrel: una entidad clínica emergente]. Revista Colombiana de Cardiología2008;15(4):172-83.">Lugo 2008</a>). </p> <p>Because antiplatelet agents act in Virchow’s triad as inhibitors of clot formation, they may be a complement to current treatment by potentially changing morbidity and mortality related to DVT, PE and PTS. </p> </section> <section id="CD012369-sec-0013"> <h3 class="title" id="CD012369-sec-0013">Why it is important to do this review</h3> <p>This review is critical at this time. VTE is a growing public health concern mainly due to an ageing population (<a href="./references#CD012369-bbs2-0080" title="TagalakisV , PatenaudeV , KahnSR , SuissaS . Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE study cohort. American Journal of Medicine2013;126(9):832.e13-21. [PMID: 23830539]">Tagalakis 2013</a>). The most serious complication of DVT is PE, where almost one‐quarter of the initial clinical presentation is sudden death (<a href="./references#CD012369-bbs2-0044" title="HeitJA . The epidemiology of venous thromboembolism in the community. Arteriosclerosis, Thrombosis, and Vascular Biology2008;28(3):370-2. [PMID: 18296591]">Heit 2008</a>). Therefore, any attempt to improve the standard treatment for DVT should be studied. Potential improvements include the reduction of the incidence of acute complications, i.e. PE and chronic complications, i.e. PTS. The treatment of a first unprovoked DVT episode in people with low or moderate risk of bleeding relies on therapeutic anticoagulation with direct oral anticoagulants preferred over heparin or vitamin K antagonists (VKAs) for at least 3 months (<a href="./references#CD012369-bbs2-0049" title="KakkosSK , GohelM , BaekgaardN , BauersachsR , Bellmunt-MontoyaS , BlackSA , et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the management of venous thrombosis. European Journal of Vacular and Endovascular Surgery2021;61(1):9-82. [PMID: 10.1016/j.ejvs.2020.09.023]">Kakkos 2021</a>). The use of inferior vena cava filters is generally reserved for high‐risk people or those with active bleeding. Additional interventions such as compression stockings are recommended for those who do not have any contraindication and aim to avoid PTS. After the initial 3 months of anticoagulation, physicians revise the risk of bleeding and examine the status of the vein with duplex ultrasound to consider either extending the anticoagulation period or stopping anticoagulation (<a href="./references#CD012369-bbs2-0049" title="KakkosSK , GohelM , BaekgaardN , BauersachsR , Bellmunt-MontoyaS , BlackSA , et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the management of venous thrombosis. European Journal of Vacular and Endovascular Surgery2021;61(1):9-82. [PMID: 10.1016/j.ejvs.2020.09.023]">Kakkos 2021</a>). </p> <p>Although some guidelines and expert consensus recognise the importance of antiplatelet agents for the treatment of DVT (<a href="./references#CD012369-bbs2-0079" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [DOI: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>), there are widely‐used guidelines regarding antithrombotic therapy for VTE disease that do not indicate any recommendations for antiplatelet agents in people with DVT (<a href="./references#CD012369-bbs2-0049" title="KakkosSK , GohelM , BaekgaardN , BauersachsR , Bellmunt-MontoyaS , BlackSA , et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the management of venous thrombosis. European Journal of Vacular and Endovascular Surgery2021;61(1):9-82. [PMID: 10.1016/j.ejvs.2020.09.023]">Kakkos 2021</a>; <a href="./references#CD012369-bbs2-0059" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. Available from www.nice.org.uk/guidance/ng158 (accessed 29 March 2022).">NICE 2020</a>). <a href="./references#CD012369-bbs2-0079" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [DOI: 10.1016/j.chest.2021.07.055]">Stevens 2021</a> suggest that aspirin can be considered for patients who stop anticoagulation treatment, but there is lack of evidence in this setting. In this review, we investigate the evidence for the use of antiplatelet agents in addition to current BMP compared to BMP (e.g. anticoagulation, compression stockings and clinical care, such as physical exercises, skin hydration, etc.) to improve the treatment of DVT concerning the presence of recurrent VTE and PTS, and if there are harms such as bleeding and mortality. We aimed to identify the best available evidence to answer these questions. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012369-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012369-sec-0014"></div> <p>To assess the effects of antiplatelet agents in addition to current BMP compared to current BMP (with or without placebo) for the treatment of DVT. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012369-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012369-sec-0015"></div> <section id="CD012369-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012369-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered RCTs examining antiplatelet agents compared to BMP following initial standard anticoagulation treatment for DVT. We considered all RCTs of antiplatelet therapy plus current BMP (including anticoagulants, compression stockings and clinical care such as physical exercises, skin hydration etc.) versus BMP with or without placebo for the treatment of DVT. We considered any antiplatelet agent by any route of administration. As this review focused on proximal DVT, we excluded trials of DVT in other regions (upper limbs, cerebral, etc.). </p> </section> <section id="CD012369-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included participants of both sexes and of any age as long as they were diagnosed with DVT (acute or chronic) by a medical specialist on clinical assessment and further investigation (duplex ultrasound, multislice computed tomography or angiography). We included both symptomatic or asymptomatic DVT. We considered the DVT as acute if it was diagnosed and treatment started within 21 days of onset of signs/symptoms and chronic if diagnosed and treatment started after 21 days (<a href="./references#CD012369-bbs2-0034" title="FlumignanRL , FlumignanCD , Baptista-SilvaJC . Angioplasty for deep venous thrombosis. Cochrane Database of Systematic Reviews2015, Issue 1. Art. No: CD011468. [DOI: 10.1002/14651858.CD011468]">Flumignan 2015</a>). We considered all participants that received any form of expected intervention or BMP (control group). For chronic DVT, we did not consider studies with anticoagulant treatment of less than 3 months because there is evidence of an increased rate of recurrence after less than 3 months of anticoagulation, but no significant difference with various longer periods of treatment (<a href="./references#CD012369-bbs2-0021" title="BoutitieF , PinedeL , SchulmanS , AgnelliG , RaskobG , JulianJ , et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ (Clinical Research ed.)2011;342:d3036. [PMID: 21610040]">Boutitie 2011</a>; <a href="./references#CD012369-bbs2-0063" title="RobertsonL , KestevenP , McCaslinJE . Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews2015, Issue 6. Art. No: CD010956. [DOI: 10.1002/14651858.CD010956.pub2]">Robertson 2015</a>). </p> </section> <section id="CD012369-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We considered the following comparisons.</p> <p>Acute DVT</p> <p> <ul id="CD012369-list-0001"> <li> <p>antiplatelet agents plus BMP versus BMP alone</p> </li> <li> <p>antiplatelet agents plus BMP versus BMP plus placebo</p> </li> </ul> </p> <p>Chronic DVT</p> <p> <ul id="CD012369-list-0002"> <li> <p>antiplatelet agents plus BMP versus BMP alone</p> </li> <li> <p>antiplatelet agents plus BMP versus BMP plus placebo</p> </li> </ul> </p> <p>We considered BMP as anticoagulation, compression stockings and clinical care, as previously defined (<a href="./references#CD012369-bbs2-0025" title="BroderickC , WatsonL , ArmonMP . Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb. Cochrane Database of Systematic Reviews2021, Issue 1. Art. No: CD002783. [DOI: 10.1002/14651858.CD002783.pub5]">Broderick 2021</a>; <a href="./references#CD012369-bbs2-0034" title="FlumignanRL , FlumignanCD , Baptista-SilvaJC . Angioplasty for deep venous thrombosis. Cochrane Database of Systematic Reviews2015, Issue 1. Art. No: CD011468. [DOI: 10.1002/14651858.CD011468]">Flumignan 2015</a>; <a href="./references#CD012369-bbs2-0049" title="KakkosSK , GohelM , BaekgaardN , BauersachsR , Bellmunt-MontoyaS , BlackSA , et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the management of venous thrombosis. European Journal of Vacular and Endovascular Surgery2021;61(1):9-82. [PMID: 10.1016/j.ejvs.2020.09.023]">Kakkos 2021</a>; <a href="./references#CD012369-bbs2-0063" title="RobertsonL , KestevenP , McCaslinJE . Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews2015, Issue 6. Art. No: CD010956. [DOI: 10.1002/14651858.CD010956.pub2]">Robertson 2015</a>; <a href="./references#CD012369-bbs2-0079" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [DOI: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>). It is important to clarify that anticoagulation means any anticoagulation therapy (heparin or oral anticoagulation or both) for more than 2 days. Since the actual role of compression stockings for DVT is still under discussion (<a href="./references#CD012369-bbs2-0015" title="AppelenD , vanLooE , PrinsMH , NeumannMH , KolbachDN . Compression therapy for prevention of post‐thrombotic syndrome. Cochrane Database of Systematic Reviews2017, Issue 9. Art. No: CD004174. [DOI: 10.1002/14651858.CD004174.pub3]">Appelen 2017</a>; <a href="./references#CD012369-bbs2-0079" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [DOI: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>), we did not exclude RCTs because they only used compression stockings in their interventions. In this review, we performed a subgroup analysis for the use of compression stockings (with and without compression stockings). In addition, we have to mention that when anticoagulation stops (e.g. 3, 6 or 12 months after the DVT diagnosis), BMP does not necessarily stop, as some BMP components may still continue to be used. </p> <p>We considered all RCTs utilising antiplatelet therapy either at the same time or after anticoagulation, and we analysed these two distinct groups separately. We did not evaluate comparisons in which antiplatelet agent use is not the only difference. </p> <p>We intended to include the utilisation of an IVC filter, but in this review we did not find such separate data. In future versions, if we find any data utilising the IVC filter, we will consider this in a subgroup analysis. </p> </section> <section id="CD012369-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We presented the outcomes at three different time points following the start of the intervention. </p> <p> <ul id="CD012369-list-0003"> <li> <p>Early outcomes (≤ 1 year after intervention)</p> </li> <li> <p>Intermediate outcomes (&gt; 1 year to ≤ 3 years after intervention)</p> </li> <li> <p>Long‐term outcomes (&gt; 3 years after intervention)</p> </li> </ul> </p> <p>Our time point of primary interest is early; we, therefore, performed primary analysis for this time point, and also planned to report the long‐term outcomes at the longest possible time of follow‐up. </p> <section id="CD012369-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012369-list-0004"> <li> <p>Recurrent VTE: including recurrent DVT and PE, first episode or recurrent, fatal or nonfatal. Both outcomes were diagnosed by clinical examination and a diagnostic assessment including ultrasonography, computed tomography or angiography. </p> </li> <li> <p>Major bleeding: defined by a decreased haemoglobin concentration of ≥ 2 g/dL, a retroperitoneal or intracranial bleed, a transfusion of ≥ 2 units of blood, or fatal haemorrhagic events, as defined by the International Society on Thrombosis and Haemostasis (<a href="./references#CD012369-bbs2-0071" title="SchulmanS , KearonC . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4. [PMID: 15842354]">Schulman 2005</a>; <a href="./references#CD012369-bbs2-0072" title="SchulmanS , AngerasU , BergqvistD , ErikssonB , LassenMR , FisherW . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. Journal of Thrombosis and Haemostasis2010;8(1):202-4. [PMID: 19878532]">Schulman 2010</a>). </p> </li> <li> <p>PE (fatal/nonfatal): confirmed by computed tomography pulmonary angiography or ventilation/perfusion (V/Q) scan, or both. </p> </li> </ul> </p> </section> <section id="CD012369-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012369-list-0005"> <li> <p>Mortality: all‐cause and VTE‐related.</p> </li> <li> <p>PTS: diagnosed by objective clinical examination (signs and symptoms), with or without the support of severity ratings such as CEAP (clinical findings, aetiological, anatomical and pathological elements), VCSS (Venous Clinical Severity Score) or Villalta scores (<a href="./references#CD012369-bbs2-0030" title="deWolfMA , WittensCH , KahnSR . Incidence and risk factors of the post-thrombotic syndrome. Phlebology/Venous Forum of the Royal Society of Medicine2012;27 Suppl 1:85-94. [PMID: 22312073]">de Wolf 2012</a>). </p> </li> <li> <p>Adverse events, such as gastrointestinal adverse effects, allergic reaction, renal failure and minor bleeding. </p> </li> <li> <p>Quality of life (QoL) or participant's subjective perception of improvement (yes or no) as reported by the study authors. If we are unable to pool data on QoL due to the use of different measurements, in future versions of this review, we will attempt to extract data on improvement (<a href="./references#CD012369-bbs2-0078" title="SoosainathanA , MooreHM , GohelMS , DaviesAH . Scoring systems for the post-thrombotic syndrome. Journal of Vascular Surgery2013;57(1):254-61. [PMID: 23182156]">Soosainathan 2013</a>). </p> </li> <li> <p>Duration of hospitalisation (days).</p> </li> </ul> </p> <p>There was no economic information in the included studies, but in future versions of this review we will report on costs or financial impacts if this is reported by study authors. </p> </section> </section> </section> <section id="CD012369-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We did not apply any language, publication year or publication status restrictions.</p> <section id="CD012369-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist conducted systematic searches of the following databases for RCTs and controlled clinical trials without language, publication year or publication status restrictions. </p> <p> <ul id="CD012369-list-0006"> <li> <p>Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web)</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021 Issue 11) via the Cochrane Register of Studies Online (CRSO) </p> </li> <li> <p>MEDLINE (Ovid MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE </p> </li> <li> <p>Embase Ovid</p> </li> <li> <p>CINAHL Ebsco</p> </li> <li> <p>AMED Ovid</p> </li> </ul> </p> <p>We developed search strategies for other databases from the search strategy designed for MEDLINE. Where appropriate, they were combined with adaptations of the highly sensitive search strategy designed by Cochrane for identifying RCTs and controlled clinical trials, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012369-bbs2-0050" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Lefebvre 2022</a>). Search strategies for major databases and trials registers are provided in <a href="./appendices#CD012369-sec-0106">Appendix 2</a> and <a href="./appendices#CD012369-sec-0107">Appendix 3</a>. </p> <p>We searched the following trials registries (<a href="./appendices#CD012369-sec-0108">Appendix 4</a>). </p> <p> <ul id="CD012369-list-0007"> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="https://who.int/trialsearch" target="_blank">who.int/trialsearch</a>) </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>) </p> </li> </ul> </p> <p>We carried out the most recent searches on 7 December 2021.</p> <section id="CD012369-sec-0025"> <h5 class="title">Authors' searches</h5> <p>We searched Latin American and Caribbean Health Science Information database (LILACS) and the Indice Bibliográfico Español de Ciencias de la Salud (IBECS) (both in <a href="http://lilacs.bvsalud.org/" target="_blank">lilacs.bvsalud.org/</a>) on 15 December 2021. See <a href="./appendices#CD012369-sec-0109">Appendix 5</a> for details of the search strategy we used. We did not use a filter but selected the RCTs manually in the LILACS and IBECS databases. Two review authors (CDQF and RLGF) configured this strategy, which was revised by the Cochrane Brazil Information Specialist and third review author (JCCBS). We searched these databases in collaboration with the Cochrane Brazil Information Specialist. </p> </section> </section> <section id="CD012369-sec-0026"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of included trials for further references regarding relevant trials. We contacted specialists in the field, manufacturers and authors of the included trials for any possible unpublished data. </p> </section> </section> <section id="CD012369-sec-0027"> <h3 class="title" id="CD012369-sec-0027">Data collection and analysis</h3> <section id="CD012369-sec-0028"> <h4 class="title">Selection of studies</h4> <p>We examined titles and abstracts to select the relevant reports after merging the search results and removing duplicate records. Two review authors (CDQF and RLGF) independently screened the trials identified by the literature search. We retrieved and examined the full text of the selected trials for compliance with the eligibility criteria. We documented the reason for exclusion of individual trials in the <a href="./references#CD012369-sec-0121" title="">Characteristics of excluded studies</a> table. We consulted a third review author (JCCBS) in the case of any disagreement. If trials included more than one type of treatment beyond those specified in the <a href="#CD012369-sec-0019">Types of interventions</a>, we used only the specific data that fit our criteria. Any appropriate method of randomisation was eligible, and we took into account any differences in methodological quality in the analyses. </p> </section> <section id="CD012369-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (CDQF and RLGF) extracted data independently and collected data on a paper data extraction form. We resolved discrepancies by discussion. We consulted a third review author (JCCBS) in the case of any disagreement. We collected the following information. </p> <p> <ul id="CD012369-list-0008"> <li> <p>Study features: publication details (e.g. year, country, authors), study design, population data (e.g. age, comorbidities, severity, duration, history concerning treatments and responses), number of participants randomised into each treatment group, number of participants in each group who failed treatment, number of participants lost to follow‐up, duration of follow‐up period </p> </li> <li> <p>Outcomes: types of outcomes measured, timing of outcomes, adverse events</p> </li> </ul> </p> </section> <section id="CD012369-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (CDQF and RLGF) independently evaluated the methodological quality of studies included in the analysis in order to assess the risk of bias according to the domains and criteria of the RoB 1 tool (<a href="./references#CD012369-bbs2-0046" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). We evaluated the bias of the following domains and characterised them as low risk, high risk or unclear risk. </p> <p> <ul id="CD012369-list-0009"> <li> <p>random sequence generation (randomisation)</p> </li> <li> <p>allocation ‐ secrecy appropriate</p> </li> <li> <p>blinding/masking of participants, assessors and results</p> </li> <li> <p>data on incomplete results</p> </li> <li> <p>selective publication of results</p> </li> <li> <p>any other potential threat to validity</p> </li> </ul> </p> <p>We reported these assessments for each study individually in the risk of bias table of the <a href="./references#CD012369-sec-0120" title="">Characteristics of included studies</a>. We contacted author(s) of included studies to seek clarification if in doubt about the data. </p> </section> <section id="CD012369-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated the risk ratios (RRs) and 95% confidence intervals (CIs) for dichotomous variables such as recurrent VTE and major bleeding, using Review Manager 5 software (<a href="./references#CD012369-bbs2-0062" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We calculated the mean difference (MD) and 95% CI for continuous variables that used similar scales such as duration of hospitalisation. We planned to calculate the standardised mean difference (MD) and 95% CI for continuous variables that used different scales such as QoL. We calculated the number needed to treat (NNT) for the outcomes with direct implication for practice (see <a href="#CD012369-sec-0100">Implications for practice</a>), using NNT = 1/(risk difference). The risk difference was obtained with Review Manager 5 software (<a href="./references#CD012369-bbs2-0062" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). As recommended by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, we expressed the NNT as 'number needed to treat for an additional beneficial outcome' (NNTB) and 'number needed to treat for an additional harmful outcome' (NNTH) to indicate direction of effect (<a href="./references#CD012369-bbs2-0074" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Schünemann 2021</a>). In future versions, if the study authors have not reported all the necessary information for this detail, we will insert the data from these non‐parametric primary studies (e.g. the effects reported as medians, quartiles, etc.) or without sufficient statistical information (e.g. deviations, number of participants, etc.) in an additional table. </p> </section> <section id="CD012369-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>We considered the individual participant as unit of analysis (unit to be distributed randomly for interventions to be compared); that is, the number of observations in the analysis should match the number of randomised participants. We grouped studies evaluating various treatment groups relevant to the review to create a single‐pair comparison. In studies that considered multiple interventions, we analysed only the data of interest. In future versions, if we find cross‐over studies and consider them appropriate for inclusion in the meta‐analysis, we will include data using the results of the paired analysis (<a href="./references#CD012369-bbs2-0032" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9. [PMID: 11914310]">Elbourne 2002</a>). </p> </section> <section id="CD012369-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the study authors for additional information where there were missing or unavailable data. In the case of no response, we reported dropout rates in the <a href="./references#CD012369-sec-0120" title="">Characteristics of included studies</a> tables of the review irrespective of the type of data. We used intention‐to‐treat analysis for assessment of the treatment effects. </p> </section> <section id="CD012369-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We quantified inconsistencies among the pooled estimates using the I<sup>2</sup> statistic (where I<sup>2</sup> = ((Q ‐ df)/Q) × 100% where Q is the χ<sup>2</sup> statistic, and df represents the degrees of freedom). This illustrates the percentage of variability in effect estimates resulting from heterogeneity rather than sampling error (<a href="./references#CD012369-bbs2-0045" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ (Clinical Research ed.)2003;327(7414):557-60. [PMID: 12958120]">Higgins 2003</a>; <a href="./references#CD012369-bbs2-0047" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> <p>As strict thresholds for interpretation of I<sup>2</sup> are not recommended, we used the guide to interpretation in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012369-bbs2-0029" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). </p> <p> <ul id="CD012369-list-0010"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ul> </p> <p>When the I² statistic lies in an area of overlap between two categories (e.g. between 50% and 60%), we planned to consider differences in participants and interventions among the studies contributing data to the analysis (<a href="./references#CD012369-bbs2-0029" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). </p> </section> <section id="CD012369-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>In future versions, we will assess reporting biases or small‐study effects by drawing a funnel plot (trial effect versus trial size) if we include a sufficient number of studies (more than 10) in the review (<a href="./references#CD012369-bbs2-0047" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD012369-sec-0036"> <h4 class="title">Data synthesis</h4> <p>We used <a href="./references#CD012369-bbs2-0062" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a> software for data analysis for statistical evaluation using an intention‐to‐treat approach. </p> <p>In accordance with section 9.5.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, "The choice between a fixed‐effect and random‐effects meta‐analysis should never be made on the basis of a statistical test for heterogeneity" (<a href="./references#CD012369-bbs2-0029" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>), we used a fixed‐effect model for analyses with very homogenous included studies considering population, intervention, comparator and outcome characteristics, or for analysis when only one study was included. If heterogeneity was detected we used a random‐effects model. </p> <p>If, in future versions, we are unable to pool data on QoL due to the use of different measurements, we will attempt to extract data on improvement (<a href="./references#CD012369-bbs2-0078" title="SoosainathanA , MooreHM , GohelMS , DaviesAH . Scoring systems for the post-thrombotic syndrome. Journal of Vascular Surgery2013;57(1):254-61. [PMID: 23182156]">Soosainathan 2013</a>). </p> </section> <section id="CD012369-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In this review version, the subgroup analysis was possible only for types of antiplatelets agents (<a href="./references#CD012369-fig-0006" title="">Analysis 1.3</a>; <a href="./references#CD012369-fig-0007" title="">Analysis 1.4</a>; <a href="./references#CD012369-fig-0008" title="">Analysis 1.5</a>; <a href="./references#CD012369-fig-0009" title="">Analysis 1.6</a> and <a href="./references#CD012369-fig-0014" title="">Analysis 3.1</a>), and for compression stockings (<a href="./references#CD012369-fig-0010" title="">Analysis 2.1</a>). However, in future versions, if possible, we will perform subgroup analyses to consider all of the following. </p> <p> <ul id="CD012369-list-0011"> <li> <p>Age</p> </li> <li> <p>Gender</p> </li> <li> <p>Different types of antiplatelet agents used</p> </li> <li> <p>Forms of administration (oral or intravenous) used for antiplatelet agents or the anticoagulation as part of the BMP </p> </li> <li> <p>Dosage of antiplatelet agents used</p> </li> <li> <p>Location of DVT</p> </li> <li> <p>Inferior vena cava filter</p> </li> <li> <p>Compression stockings</p> </li> </ul> </p> <p>If we find substantial heterogeneity in future, and there are sufficient data, we will investigate the possible causes and further explore the impact of the condition of participants and interventions (i.e. participant characteristics, adjuvant drugs) using subgroup analyses. We will test for subgroup differences using interaction tests. </p> </section> <section id="CD012369-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>In future versions of this review, if there are sufficient studies, we will perform sensitivity analyses using only low risk of bias studies according to allocation concealment and blinding of outcome assessors. We will present these results and compare them with the overall findings. </p> </section> <section id="CD012369-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to interpret the findings of this review (<a href="./references#CD012369-bbs2-0040" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ (Clinical Research ed.)2004;328(7454):1490-4. [PMID: 15205295]">GRADE Working Group</a>). We developed a summary of findings table for each comparison using <a href="./references#CD012369-bbs2-0039" title="McMaster University (developed by Evidence Prime)GRADEpro GDT Guideline Development Tool. Version accessed 6 March 2018. Hamilton (OH): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a> software. We included the following outcomes: recurrent VTE, major bleeding, PE, mortality, PTS and adverse events. We assessed the certainty of the body of evidence by considering the overall risk of bias in the included studies, the directness of the evidence, the inconsistency of the results, the precision of the estimates and the risk of publication bias (<a href="./references#CD012369-bbs2-0040" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ (Clinical Research ed.)2004;328(7454):1490-4. [PMID: 15205295]">GRADE Working Group</a>; <a href="./references#CD012369-bbs2-0073" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>). We based the tables on methods described in Chapters 11 and 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012369-bbs2-0047" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>); we justified any departures from the standard methods. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012369-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012369-sec-0040"></div> <section id="CD012369-sec-0041"> <h3 class="title">Description of studies</h3> <section id="CD012369-sec-0042"> <h4 class="title">Results of the search</h4> <p>Our searches identified 19,241 records from database and author searches. Out of the 19,241 total initial references, we obtained 11,314 records after duplicates were removed. Of these 11,314 records, we assessed 11,254 as not relevant for this review for different reasons (e.g. participants not humans, different design of study, disease is not assessed in this review, etc). For the remaining 60 records (40 studies), we assessed the full text for eligibility. Out of the 40 studies, we excluded seven (<a href="./references#CD012369-sec-0121" title="">Characteristics of excluded studies</a>), we assessed 27 studies as not relevant for this review and six studies as eligible for inclusion (<a href="./references#CD012369-sec-0120" title="">Characteristics of included studies</a>). See <a href="#CD012369-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012369-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012369-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We contacted all authors of the included studies, as well as pharmaceutical companies, in order to find out if there were any ongoing studies. When we received a response, it was negative for new data. </p> </section> <section id="CD012369-sec-0043"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD012369-sec-0120" title="">Characteristics of included studies</a>. </p> <section id="CD012369-sec-0044"> <h5 class="title">Design and setting</h5> <p>We found six studies (18 records) with 1625 eligible participants to include in our analysis (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>; <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>; <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>; <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>; <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>). Not all participants in these six studies (2138) were included in this review because only a fraction of them corresponded with our inclusion criteria. In <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>, the study authors evaluated a group without any treatment (without anticoagulation) in acute DVT (100 participants), which could not be included in our analysis because it is not acceptable BMP. <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> also evaluated a group without treatment, but in the chronic phase of DVT, i.e. the participants had already received an initial treatment of anticoagulants for 6 months before randomisation. <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> evaluated participants with DVT, participants with DVT plus PE and participants with PE without diagnosed DVT. The <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> participants with PE without diagnosed DVT were not part of this review and therefore not evaluated. Only data for the outcome 'recurrent VTE' were stratified by type of participant and could therefore be included in the analysis in this review. For the <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> trial, the ASPIRE authors provided us with separate data for the group with DVT with or without PE, making it possible to use the study results. </p> <p>The six included studies provided data for three different comparisons.</p> <p> <ul id="CD012369-list-0012"> <li> <p>Acute DVT ‐ antiplatelet agents plus BMP versus BMP (500 participants; <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>) </p> </li> <li> <p>Chronic DVT ‐ antiplatelet agents plus BMP versus BMP (224 participants; <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>) </p> </li> <li> <p>Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo (901 participants; <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>; <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>; <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>) </p> </li> </ul> </p> <p><a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> provided information about study duration (between May 2004 and August 2010) and setting; the protocol indicated that participants were to be collected from 25 medical centres in Austria, Denmark, France, Great Britain, Italy and the Netherlands. In <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>, study duration was between May 2003 and August 2011, and recruitment was from 56 sites in five countries (Argentina, Australia, India, New Zealand, Canada). All other included studies did not provide details about study period or the collection setting. However, the study reports do mention affiliate countries such as Italy and the UK (<a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>), Belgium (<a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>), the USA (<a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>), and Canada and USA (<a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>). </p> </section> <section id="CD012369-sec-0045"> <h5 class="title">Participants</h5> <p>All the studies included men and women, with ages ranging from 19 to 77 years, with the majority older than 40. Two studies had a majority of female participants (52% in <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>; 65% in <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>). The four remaining studies had more male participants (54% in <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>, 68% in <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; 73% in <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>; and 64% in <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>). <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> reported that the vein segment with DVT was proximal for all participants, and <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> described enrolment of participants with DVT in the popliteal vein or in proximal leg veins. <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> had more than 75% of participants with DVT only in distal settings and less than 20% only in the proximal setting, although the information about DVT setting was not available for each outcome. None of the other included studies mentioned the site of DVT. The participants presented different causes that led to DVT and had variable degrees of signs/symptoms. However, two studies mentioned the proportion of participants without an underlying cause of DVT (45% in <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; 68% in <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>). </p> <p><a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>, <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>, <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>, <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> and <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> studied participants with chronic DVT (treatment started after 21 days of symptoms), while <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> studied acute DVT (treatment started before 21 days of symptoms) in participants with severe or recurrent DVT. </p> <p>All studies reported that patients with clinical factors which prohibited antiplatelet agent use or patients who required vitamin K antagonists (VKA) were excluded from participation. </p> <p>Despite attempts to contact the studies’ authors, not all responded or provided the raw data for analysis. All participants analysed in this review had at least one episode of DVT (with or without PE) confirmed by an objective further investigation, such as Doppler vascular ultrasound, multislice computed tomography or angiography. We did not include in the analysis participants whose confirmation of DVT was not possible. Because of this, we could only analyse part of the data from <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> and <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> (the ASPIRE group provided additional data by personal communication). </p> </section> <section id="CD012369-sec-0046"> <h5 class="title">Interventions and co‐treatments</h5> <p>All included studies evaluated antiplatelet agents in the intervention group with some differences. <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> and <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> compared antiplatelet agents plus BMP versus BMP without placebo (<a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> in the acute phase and <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> in the chronic phase of DVT). <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>, <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>, <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> and <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> compared antiplatelets plus BMP with BMP plus placebo. <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> used antiplatelet agents concomitant with anticoagulants (VKA); all other studies used antiplatelet agents only after the initial treatment with anticoagulants was stopped or did not use initial anticoagulation (<a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>). </p> <p>There are two reports from the same author group that had very similar study aims (<a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>), specifically the design and number in each group. Since the study authors did not respond to our correspondence, we assumed that both reports show data from the same group of participants and treated both as complementary information to each other. <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> described treatment with antiplatelet agents for the first episode of DVT after 6 months of dicumarol to keep the prothrombin time below 30%. After the discontinuation of VKA and normalisation of coagulation blood rates, the 224 participants were randomised into four groups: </p> <p> <ul id="CD012369-list-0013"> <li> <p>indobufen (200 mg twice/day);</p> </li> <li> <p>graduated elastic compression stockings;</p> </li> <li> <p>indobufen (200 mg twice/day) and graduated elastic compression stockings;</p> </li> <li> <p>no treatment.</p> </li> </ul> </p> <p>In our analyses, we considered the groups separately according to the use of compression stockings (subgroup analysis) and together for meta‐analysis independent of compression stocking use. </p> <p><a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> described six groups in the study without mention of compression stockings. In the acute phase of an episode of DVT classified by the group as severe (described in this study as cases when multiple risk factors were present in healthy participants, and when the three components of Virchow’s triad were present simultaneously, resulting in a formation of mixed thrombi or thrombi richer in platelets than fibrin) or recurrent DVT, 600 participants were randomised as follows. </p> <p> <ul id="CD012369-list-0014"> <li> <p>100 without treatment (excluded from our review because this is not BMP for acute DVT) </p> </li> <li> <p>100 with acenocoumarol (once/day to maintain prothrombin time of 20% to 30%, international normalised ratio (INR) 2.5 to 3.5, activated recalcification time 1.5 to 2 × normal and activated partial thromboplastin time test 1.5 to 2 × normal) </p> </li> <li> <p>100 with acenocoumarol (once/day) and piracetam (4 × 2.4 g/day)</p> </li> <li> <p>100 with acenocoumarol (once/day) and buflomedil (2 × 300 mg/day)</p> </li> <li> <p>100 with acenocoumarol (once/day) and pentoxifylline (3 × 400 mg/day)</p> </li> <li> <p>100 with acenocoumarol (once/day) and dipyridamole (2 × 200 mg/day)</p> </li> </ul> </p> <p><a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> evaluated 38 participants with recurrent DVT (chronic phase with or without PE) during anticoagulation with warfarin, which was withdrawn after recurrence and before randomisation into two groups. </p> <p> <ul id="CD012369-list-0015"> <li> <p>19 with dipyridamole (4 × 25 mg/day) and aspirin (4 × 300 mg/day) by mouth</p> </li> <li> <p>19 with placebo (4 × a day) by mouth</p> </li> </ul> </p> <p>The treatment was continued for 18 months or until a DVT was confirmed angiographically or an adverse effect was described. <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> did not mention the utilisation of compression stockings. </p> <p><a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> randomised 41 participants with idiopathic recurrent DVT into three groups: </p> <p> <ul id="CD012369-list-0016"> <li> <p>14 with sulfinpyrazone (1 × 800 mg/day) orally;</p> </li> <li> <p>ethylestrenol and phenformin (this group was not utilised in this review because they are not antiplatelet agents); and </p> </li> <li> <p>14 with placebo (no details about dosage).</p> </li> </ul> </p> <p>In the year prior to the study, all participants presented with at least one episode of recurrent DVT with a minimum of one positive venogram. Twenty of these 41 participants were anticoagulated before and during the study. Of these 20, 11 took warfarin and 9 received subcutaneous heparin, but the outcomes were not described separately. After that, 10 additional participants (all men) with recurrent venous thrombosis were studied regarding anticoagulation effects without randomisation and were therefore not included in our review. The study authors did not mention the use of compression stockings. </p> <p><a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> described 403 participants who had their first‐ever unprovoked VTE and completed 6 to 18 months of oral anticoagulant treatment before randomisation into two groups: aspirin 100 mg daily or placebo daily for at least 2 years. The study authors did not mention the use of compression stockings. Since this primary study evaluated an intervention for VTE, they included participants with only DVT, only PE and DVT/PE. Despite the fact that the study authors described the number of participants with these specific characteristics, they did not present all outcomes separately for each index event. We contacted the study authors for clarification but did not receive an answer. Therefore, only the 252 participants for whom the outcomes could be assessed separately in the reports were included in our review. </p> <p><a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> randomised 822 participants with first‐episode of unprovoked VTE, after the cessation of anticoagulation therapy (duration of anticoagulation from 6 weeks to 24 months). Two groups were randomised: the first received aspirin 100 mg daily, and the second received matching placebo daily, for at least 2 years. The <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> authors kindly provided us with raw data for inclusion in this review. Our group of interest (DVT with or without PE) had 583 participants and was included in this review. </p> </section> <section id="CD012369-sec-0047"> <h5 class="title">Sample size</h5> <p><a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> and <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> had all participants included in our review (224 and 38, respectively). From <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>, <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>, <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> and <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>, we included in our review only a portion of the original participants (500 of 600, 41 of 51, 252 of 403, and 583 of 822, respectively). <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> described the power calculation of 80% to detect a relative risk reduction (RRR) of 35% in favour of aspirin compared with placebo in their protocol document, but in their report the RRR was 40% with an alpha error of 5%. <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> reported an 80% power to detect a 32% reduction in major vascular events, their secondary outcome described. All other included studies did not describe a power calculation in the available documents. </p> </section> <section id="CD012369-sec-0048"> <h5 class="title">Length of follow‐up</h5> <p><a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> randomised the participants 7 months after the first episode of DVT with 6 months of prior anticoagulant treatment. After the initial evaluation, they were studied every 3 months after randomisation and every time they had signs or symptoms (swelling, pain, tenderness, increase in calf/ankle section, or local temperature increase) over a 3‐year period. </p> <p><a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> evaluated participants with severe and/or recurrent DVT in the acute phase, assessed every 8 days for the first month after the randomisation and monthly for the next 3 to 6 months. </p> <p><a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> studied subjects with recurrent DVT despite the initial treatment with warfarin for at least 6 months. After 2 to 4 months without warfarin, and after the measurement of baseline platelet survival time normalised, the participants were randomised and followed for up to 18 months or until a venographically‐confirmed DVT or an adverse drug reaction occurred. </p> <p><a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> utilised data of participants with recurrent DVT confirmed by at least one positive venogram. The initial episode of DVT was from 1 year to 6 years before the beginning of the study, and the follow‐up period after randomisation was 3 months. </p> <p><a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> analysed participants with an initial unprovoked DVT after 6 months to 18 months of oral anticoagulant treatment and randomised them in two groups: placebo and aspirin (100 mg once daily). Participants were re‐examined every 3 months during the first year after randomisation and every 6 months thereafter. The median duration of the study treatment was 24 months for the aspirin group and 23.5 months for the placebo group. Exceptional cases were described in the reports. </p> <p><a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> included participants with their first unprovoked DVT after their anticoagulant treatment finished (from 6 weeks to 24 months). The two groups who were randomised were analysed after 1 month and 6 months until the end of follow‐up. Between visits, they were contacted (email or telephone) quarterly. The duration of treatment had a median of 37.2 months. </p> </section> <section id="CD012369-sec-0049"> <h5 class="title">Outcomes</h5> <p>The <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> study presented data on recurrent DVT, major bleeding and mortality. Since all subjects finished the study without side effects, we assumed that they did not die or experience any adverse events. There was no explanation as to what was considered major bleeding or if there was any; the trial authors only cited that "no side‐effects were recorded during the three‐year follow‐up period". </p> <p><a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> described some of our primary (major bleeding) and secondary (mortality, PTS at 6 months and adverse events) outcomes of interest. However, there was no explanation about what was considered major bleeding, and the study authors did not utilise a validated method to assess PTS. They used a subjective vision of the participant to assess PTS. The study authors also evaluated other outcomes such as clinical assessments (including embolisation) and ultrasound assessments using a non‐validated 6‐point scale. Individual components of the score were not reported separately. The study authors also studied alterations in laboratory tests, such as platelet count and aggregation tests, ß‐thromboglobulin, platelet factor 4, fibrinogen, factor VIII, fibrinopeptide A, antithrombin III, protein C, protein S, global tests of coagulation and blood and plasma viscosity. In the results, the study authors presented data regarding gastrointestinal symptoms, headache, severe and moderate bleeding that were analysed as adverse events. All participants were cited at the end of the study, so we assumed that all participants completed the follow‐up and no one died. </p> <p><a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> described recurrent DVT (objectively confirmed by venography) and PE. The study authors also cited platelet survival time, which is not a relevant outcome for this review. The study authors described adverse side effects, such as peptic ulcers and epigastric pain that were analysed as our adverse event outcome. The study authors did not describe any deaths, and all participants were present in the results. Therefore, we included this study in the assessment of mortality. </p> <p><a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> presented data about recurrent DVT confirmed by venography, adverse events and mortality, which are relevant outcomes for this review. The study authors also reported data on platelet and fibrinogen survival time that are not relevant to our analysis. PE is an important outcome, but was not mentioned by study authors. <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> described some adverse side effects, such as gastrointestinal distress (n = 1), emotional difficulties (n = 1) and lethal stroke (n = 1) that were addressed in the adverse events outcome. </p> <p><a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> evaluated several relevant outcomes for this review (recurrence of VTE objectively confirmed, major bleeding, mortality (any cause) and adverse events). However, only data on recurrence of VTE were available in the study reports for the specific population with DVT as an index diagnosis. Despite our attempts to contact the study authors, we did not receive any additional data that could be analysed in our review. We could not analyse results about major bleeding, mortality or adverse events from <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> because the available study data were not reported separately for participants with DVT or PE. The study authors also reported the following outcomes: acute ischaemia of the lower limbs, unstable angina, nonfatal myocardial infarction, stroke and transient ischaemic attack, and additional necessity of antiplatelets and anticoagulant therapy that were not relevant for this review. </p> <p><a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> assessed many outcomes as planned in our protocol, such as recurrent VTE, major bleeding, PE fatal/non‐fatal, mortality separately in all‐cause and VTE‐related, duration of hospitalisation and adverse events (gastrointestinal (n = 26), minor bleeds (n = 6) and respiratory cause (n = 16)). This data were kindly provided by the ASPIRE team through email contact. </p> <p>None of the included studies presented all outcomes of interest in this review, but all included studies reported at least one primary outcome as planned in our protocol (<a href="./references#CD012369-bbs2-0087" title="FlumignanCD , FlumignanRL , Baptista-SilvaJC . Antiplatelet agents for the treatment of deep venous thrombosis. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012369. [DOI: 10.1002/14651858.CD012369]">Flumignan 2016</a>). Costs and financial aspects were not cited in any included study. </p> </section> </section> <section id="CD012369-sec-0050"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD012369-sec-0121" title="">Characteristics of excluded studies</a> table. </p> <p>We excluded seven studies (<a href="./references#CD012369-bbs2-0007" title="BickRL , NixMK , SkondiaV . THe effect of piracetam in preventing recurrent deep venous thrombosis. Thrombosis and Haemostasis1981;46(1):91. [ISSN 0340-6245]">Bick 1981</a>; <a href="./references#CD012369-bbs2-0008" title="EUCTR2013-000619-26. Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism (The Einstein Choice Study). clinicaltrialsregister.eu/ctr-search/trial/2013-000619-26/AT (first received 12 February 2014). EUCTR2013-000619-26-HU. Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism. The Einstein Choice Study - Reduced-dosed rivaroxaban in the long-term prevention of recurrent symptomatic VTE. trialsearch.who.int/?trialid=EUCTR2013-000619-26-HU (first received 11 March 2014). NCT02064439. Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT02064439 (first received 17 February 2014). Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus aspirin in the long-term prevention of blood clots from recurring in the leg or lung. explorer.opentrials.net/trials/cc5722b3-d0bc-4a7d-a9d1-35d8391aac9c2014;(accessed 4 December 2016). WeitzJI , BauersachsR , Beyer-WestendorfJ , BounameauxH , BrightonTA , CohenAT , et al. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Thrombosis and Haemostasis2015;114(3):645-50. [PMID: 25994838]WeitzJI , LensingAW , PrinsMH , RupertB , JanBW , BounameauxH , et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. New England Journal of Medicine2017;376(13):1211-22. [DOI: 10.1056/NEJMoa1700518]">EINSTEIN CHOICE</a>; <a href="./references#CD012369-bbs2-0009" title="EvansG , GentM . Effect of platelet suppressive drugs on arterial and venous thromboembolism. In: CadeJF , HirshJ , GallusAS , SchönbaumE , editors(s). Platelets, drugs and thrombosis. Basel: Karger, 1975:258-62. [DOI: 10.1159/000395715]">Evans 1975</a>; <a href="./references#CD012369-bbs2-0010" title="IRCT20200202046344N1. Comparison of the effectiveness of aspirin with enoxaparin sodium for prevention of deep vein thrombosis in tibial fractures. en.irct.ir/trial/49703 (first received 29 September 2020). ">IRCT20200202046344N1</a>; <a href="./references#CD012369-bbs2-0011" title="MoriauM , Col-De BeysC , PardongeE , FerrantA . Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.). Thrombosis and Haemostasis1982;47(1):27-31. [PMID: 6280332]">Moriau 1982</a>; <a href="./references#CD012369-bbs2-0012" title="NielsenHK , HustedSE , KrusellL , FastingH , CharlesP , HansenHH , et al. Anticoagulant therapy in deep venous thrombosis. A randomized controlled study. Thrombosis and Haemostasis1985;54(1):233. NielsenHK , HustedSE , KrusellLR , FastingH , CharlesP , HansenHH , et al. Anticoagulant therapy in deep venous thrombosis. A randomized controlled study. Thrombosis Research1994;73(3-4):215-26. [PMID: 8191414]NielsenHK , HustedSE , KrusellLR , FastingH , CharlesP , HansenHH . Silent pulmonary embolism in patients with deep venous thrombosis. Incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. Journal of Internal Medicine1994;235(5):457-61. [PMID: 8182402]">Nielsen 1994</a>; <a href="./references#CD012369-bbs2-0013" title="SidhuVS , GravesSE , BuchbinderR , NaylorJM , PrattNL , SteigerRS , et al. CRISTAL: protocol for a cluster randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study. BMJ Open2019;9(11):e031657. [DOI: 10.1136/bmjopen-2019-031657]SidhuVS , KellyTL , PrattN , GravesS , BuchbinderR , NaylorJ , et al. CRISTAL (a cluster-randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study): statistical analysis plan. Trials2021;22(1):564. [DOI: 10.1186/s13063-021-05486-0]">Sidhu 2019</a>). </p> <p>We excluded two studies because the DVT diagnosis was not objectively confirmed, as described in our protocol (<a href="./references#CD012369-bbs2-0007" title="BickRL , NixMK , SkondiaV . THe effect of piracetam in preventing recurrent deep venous thrombosis. Thrombosis and Haemostasis1981;46(1):91. [ISSN 0340-6245]">Bick 1981</a>; <a href="./references#CD012369-bbs2-0009" title="EvansG , GentM . Effect of platelet suppressive drugs on arterial and venous thromboembolism. In: CadeJF , HirshJ , GallusAS , SchönbaumE , editors(s). Platelets, drugs and thrombosis. Basel: Karger, 1975:258-62. [DOI: 10.1159/000395715]">Evans 1975</a>). In <a href="./references#CD012369-bbs2-0007" title="BickRL , NixMK , SkondiaV . THe effect of piracetam in preventing recurrent deep venous thrombosis. Thrombosis and Haemostasis1981;46(1):91. [ISSN 0340-6245]">Bick 1981</a>, the study authors did not provide an acceptable additional confirmation for DVT diagnosis, and in <a href="./references#CD012369-bbs2-0009" title="EvansG , GentM . Effect of platelet suppressive drugs on arterial and venous thromboembolism. In: CadeJF , HirshJ , GallusAS , SchönbaumE , editors(s). Platelets, drugs and thrombosis. Basel: Karger, 1975:258-62. [DOI: 10.1159/000395715]">Evans 1975</a> the diagnosis of DVT was only by clinical symptoms and signs. <a href="./references#CD012369-bbs2-0011" title="MoriauM , Col-De BeysC , PardongeE , FerrantA . Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.). Thrombosis and Haemostasis1982;47(1):27-31. [PMID: 6280332]">Moriau 1982</a> studied a drug (suloctidil) that was voluntarily withdrawn worldwide in 1985 by the manufacturer due to several cases of hepatitis associated with its use, some of them fatal (<a href="./references#CD012369-bbs2-0082" title="United Nations. Consolidated list of products: whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments. Economic &amp; Social Affairs2005;(12):251.">UN 2005</a>). In <a href="./references#CD012369-bbs2-0012" title="NielsenHK , HustedSE , KrusellL , FastingH , CharlesP , HansenHH , et al. Anticoagulant therapy in deep venous thrombosis. A randomized controlled study. Thrombosis and Haemostasis1985;54(1):233. NielsenHK , HustedSE , KrusellLR , FastingH , CharlesP , HansenHH , et al. Anticoagulant therapy in deep venous thrombosis. A randomized controlled study. Thrombosis Research1994;73(3-4):215-26. [PMID: 8191414]NielsenHK , HustedSE , KrusellLR , FastingH , CharlesP , HansenHH . Silent pulmonary embolism in patients with deep venous thrombosis. Incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. Journal of Internal Medicine1994;235(5):457-61. [PMID: 8182402]">Nielsen 1994</a> the antiplatelet agent group did not receive BMP with the intervention, as we prespecified in our protocol. Finally, it was not possible to utilise <a href="./references#CD012369-bbs2-0008" title="EUCTR2013-000619-26. Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism (The Einstein Choice Study). clinicaltrialsregister.eu/ctr-search/trial/2013-000619-26/AT (first received 12 February 2014). EUCTR2013-000619-26-HU. Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism. The Einstein Choice Study - Reduced-dosed rivaroxaban in the long-term prevention of recurrent symptomatic VTE. trialsearch.who.int/?trialid=EUCTR2013-000619-26-HU (first received 11 March 2014). NCT02064439. Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT02064439 (first received 17 February 2014). Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus aspirin in the long-term prevention of blood clots from recurring in the leg or lung. explorer.opentrials.net/trials/cc5722b3-d0bc-4a7d-a9d1-35d8391aac9c2014;(accessed 4 December 2016). WeitzJI , BauersachsR , Beyer-WestendorfJ , BounameauxH , BrightonTA , CohenAT , et al. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Thrombosis and Haemostasis2015;114(3):645-50. [PMID: 25994838]WeitzJI , LensingAW , PrinsMH , RupertB , JanBW , BounameauxH , et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. New England Journal of Medicine2017;376(13):1211-22. [DOI: 10.1056/NEJMoa1700518]">EINSTEIN CHOICE</a>, <a href="./references#CD012369-bbs2-0010" title="IRCT20200202046344N1. Comparison of the effectiveness of aspirin with enoxaparin sodium for prevention of deep vein thrombosis in tibial fractures. en.irct.ir/trial/49703 (first received 29 September 2020). ">IRCT20200202046344N1</a>, and <a href="./references#CD012369-bbs2-0013" title="SidhuVS , GravesSE , BuchbinderR , NaylorJM , PrattNL , SteigerRS , et al. CRISTAL: protocol for a cluster randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study. BMJ Open2019;9(11):e031657. [DOI: 10.1136/bmjopen-2019-031657]SidhuVS , KellyTL , PrattN , GravesS , BuchbinderR , NaylorJ , et al. CRISTAL (a cluster-randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study): statistical analysis plan. Trials2021;22(1):564. [DOI: 10.1186/s13063-021-05486-0]">Sidhu 2019</a> data because there is not a comparison of interest for this review; they did not use a control group with BMP or BMP plus placebo. </p> </section> </section> <section id="CD012369-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD012369-fig-0002">Figure 2</a> and <a href="#CD012369-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012369-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: 'Review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012369-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: 'Review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012369-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: 'Review authors' judgements about each risk of bias item for each included study." data-id="CD012369-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: 'Review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012369-sec-0052"> <h4 class="title">Allocation</h4> <p><a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> provided details of randomisation sequence and allocation. The study authors cited a computer‐generated randomisation sequence, with a 1:1 proportion of aspirin/placebo, and they used consecutive box numbers for allocation. Therefore, we classified <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> at low risk for selection bias. </p> <p>We also classified <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> at low risk for selection bias. In the protocol, the study authors described randomisation by a central web‐based system, with stratification by centre and by duration of oral anticoagulation therapy prior to the beginning of study treatment. </p> <p><a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>, <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>, <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> and <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> did not report details about how randomisation was performed or how allocation was guaranteed. Since they only cited that they were randomised trials, we classified these four studies at ‘unclear risk’ for selection bias. </p> </section> <section id="CD012369-sec-0053"> <h4 class="title">Blinding</h4> <p><a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> divided the participants into a treatment group (with oral indobufen) and a control group without oral treatment or a placebo. As the participants and personnel were not blinded, we classified it at high risk. The study authors wrote that "all participants were routinely scanned with colour Doppler ultrasound (CDS) every 3 months and every time that they had new signs or symptoms (swelling, pain, tenderness, increase in calf/ankle section, local temperature increase)". Since the participants were not blinded, the outcomes were not blind, and we judged the blinding of outcome assessors to be high risk as well. </p> <p>Despite the phrase "randomised, prospective blind study", we classified <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> at high risk of bias for blinding of participants and personnel because we deemed it almost impossible to maintain blinding of participants in a control group without a placebo, while the intervention groups had several differences in the number of tablets per day (1 to 4 doses per day). We classified detection bias at unclear risk of bias because there were no details provided. </p> <p><a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> stated that "patients were randomly assigned (double‐blind)" and all tablets in the two groups were taken four times a day. Therefore, we classified this study at low risk of bias for blinding of participants and personnel. We classified the risk of detection bias of the <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> study as unclear because this was not mentioned. </p> <p>We classified <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> as unclear for both performance and detection bias because they did not describe any information about blinding of participants and personal or blinding of outcome assessors. </p> <p>In <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>, the treatment regimens (antiplatelets and placebo) were similar, with one tablet once daily. The study authors utilised a central, independent adjudication committee for all suspected study outcome events "whose members were unaware of the group assignments and who reviewed the imaging results". Therefore, we judged this study at low risk for both performance and detection bias. </p> <p><a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> had similar treatment regimens, with one tablet once daily of aspirin or matching placebo. All suspected outcome events were assessed by an outcome committee who were unaware of the randomisation and treatment. We classified <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> at low risk for performance and detection bias. </p> </section> <section id="CD012369-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>We classified <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> at high risk of attrition bias because the study authors reported that all included participants concluded the analysis, but there were dropouts in all groups with no further explanation. </p> <p>We classified <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> at high risk of attrition bias because losses and exclusions were not detailed. The outcome PE was mentioned as clinically assessed, but it was not presented in the study results. </p> <p>Although the losses and exclusions were not detailed, we classified both <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> and <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> at low risk of attrition bias because apparently all participants concluded the studies. The same number of participants was observed at the beginning and at the end of the study. Adverse events were not preplanned outcomes but were mentioned in the results in these trials. </p> <p>We classified <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> at low risk of attrition bias, because losses and exclusions were detailed, and the study authors utilised an intention‐to‐treat approach. The adverse events were mentioned and analysed. </p> <p>We also classified <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> at low risk of attrition bias. <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> described all losses/exclusions, and all participants were analysed by an intention‐to‐treat approach. </p> </section> <section id="CD012369-sec-0055"> <h4 class="title">Selective reporting</h4> <p>We classified both <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> and <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> at high risk of reporting bias because the full protocols were not available (only report information) and <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> has not reported prespecified outcomes that are of interest to the review (e.g. PE). </p> <p>The protocol of the <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> study was available and the details were reported. The study authors stated that "the study was performed in accordance with the protocol and with the provisions of the Declaration of Helsinki and local regulations". However, the 'historical versions' in ClinicalTrials.gov record state that the <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> protocol was modified for its primary and secondary outcomes prior to the study publication, putting it at high risk of selective reporting. </p> <p>We classified <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> at unclear risk of bias, because the full protocol is not available (only report information), and only one primary outcome that is of interest in the review (recurrent DVT) was prespecified and reported. PE was mentioned as a previous disease, but it was not in the results, possibly due to the lack of events in a short follow‐up (3 months). Bleeding was also not mentioned. </p> <p>We classified <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> at low risk of bias because, even though the full protocol is not available (only report information), some primary outcomes that are of interest in the review (PE and recurrent DVT) were preplanned or reported. </p> <p><a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>'s protocol is available in the Australian New Zealand Clinical Trials Registry and, when we assessed the history of modification, there were no great changes in the outcome measures. Because of that, we classified it at low risk of selective reporting bias. </p> </section> <section id="CD012369-sec-0056"> <h4 class="title">Other potential sources of bias</h4> <p>We judged <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> at high risk of bias because we suspect duplicate publication. Two reports were published in the same year by the same authors' group citing similar data without clear explanation in the text. We contacted the authors, but we have not received additional information. </p> <p>We suspect <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> of pharmaceutical company support (two author affiliations) without clear mention in the report. Because of this, we classified it at high risk of bias. </p> <p>We classified <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> at high risk for several reasons. The study included one group treated with warfarin after randomisation. Moreover, the investigators used different anticoagulation treatments (warfarin or heparin) for some participants during the study, and this was not sufficiently described. There are no details about the numbers of anticoagulated participants in each group. </p> <p>We classified <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>, <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> and <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> at low risk of bias because we did not identify any other reason for bias. </p> </section> </section> <section id="CD012369-sec-0057"> <h3 class="title" id="CD012369-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD012369-tbl-0001"><b>Summary of findings 1</b> Acute DVT ‐ antiplatelet agents plus BMP compared to BMP alone for the treatment of DVT</a>; <a href="./full#CD012369-tbl-0002"><b>Summary of findings 2</b> Chronic DVT ‐ antiplatelet agents plus BMP compared to BMP alone for the treatment of DVT</a>; <a href="./full#CD012369-tbl-0003"><b>Summary of findings 3</b> Chronic DVT ‐ antiplatelet agents plus BMP compared to BMP plus placebo for the treatment of DVT</a> </p> <p>None of the studies included in this review contained data for the comparison of ‘acute DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo’. </p> <section id="CD012369-sec-0058"> <h4 class="title">Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone</h4> <p>For this comparison, we had data from one study with a short follow‐up time (<a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>). </p> <section id="CD012369-sec-0059"> <h5 class="title">Primary outcomes</h5> <section id="CD012369-sec-0060"> <h6 class="title">Recurrent venous thromboembolism (VTE)</h6> <p><a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> did not report data for this outcome. Embolisation was reported as part of a 6‐point scale used for clinical and ultrasonic assessment of efficacy. Components of the score were not reported separately. </p> </section> <section id="CD012369-sec-0061"> <h6 class="title">Major bleeding</h6> <p>The study authors reported no major bleeding events during the follow‐up period. Therefore, we could not estimate the effect of this outcome with the available data. </p> </section> <section id="CD012369-sec-0062"> <h6 class="title">Pulmonary embolism (PE) (fatal/nonfatal)</h6> <p>Although the study authors provided information about PE in the baseline characteristics of participants, PE was not an outcome reported in the results. Embolisation was reported as part of a 6‐point scale used for clinical and ultrasonic assessment of efficacy. Components of the score were not reported separately. </p> </section> </section> <section id="CD012369-sec-0063"> <h5 class="title">Secondary outcomes</h5> <section id="CD012369-sec-0064"> <h6 class="title">Mortality</h6> <p>Since all participants were included in the final results of <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>, we concluded there were no deaths. We could not estimate the effect of this outcome as follow‐up was limited to 6 months. </p> </section> <section id="CD012369-sec-0065"> <h6 class="title">Post‐thrombotic syndrome (PTS)</h6> <p>When all types of antiplatelet agents were evaluated together, <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> presented data with a lower risk of PTS in the antiplatelet plus BMP group compared with the control group (risk ratio (RR) 0.74, 95% confidence interval (CI) 0.61 to 0.91; 1 study, 500 participants; very low‐certainty evidence). Moderate heterogeneity was observed among the different antiplatelet subgroups (<a href="./references#CD012369-fig-0006" title="">Analysis 1.3</a>). </p> <p>We performed a subgroup analysis by type of antiplatelet agent, which presented a favourable effect for piracetam and buflomedil but not for pentoxifylline or dipyridamole (<a href="./references#CD012369-fig-0007" title="">Analysis 1.4</a>). In the piracetam (4 x 2.4 g/day) and buflomedil (2 x 300 mg/day) results, there was a difference favouring the antiplatelet plus BMP group without important heterogeneity (RR 0.57, 95% CI 0.42 to 0.79; 1 study, 250 participants; I<sup>2</sup> = 0; very low‐certainty evidence; <a href="./references#CD012369-fig-0007" title="">Analysis 1.4</a>). However, the collective results for pentoxifylline (3 x 400 mg/day) and dipyridamole (2 x 200 mg/day), did not indicate a clear difference between the antiplatelet plus BMP and the control groups without important heterogeneity (RR 0.90, 95% CI 0.69 to 1.17; 1 study, 250 participants; I<sup>2</sup> = 20%; very low‐certainty evidence; <a href="./references#CD012369-fig-0007" title="">Analysis 1.4</a>). Statistical tests for subgroup differences revealed a difference between the pooled antiplatelet subgroups (P = 0.03). </p> </section> <section id="CD012369-sec-0066"> <h6 class="title">Adverse events</h6> <p><a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> reported adverse events as a percentage interval in each group, e.g. 3% to 4% moderate bleeding (haematoma, haematuria) in each group, 5% to 10% gastrointestinal symptoms in the pentoxifylline group, and 10% to 20% headache in the dipyridamole group. For the estimation of the results in this review, we assumed the biggest value of the reported interval as the number of adverse events in each group. There was a higher risk of adverse events for the antiplatelet plus BMP group than for the control group, without important heterogeneity, when all types of antiplatelet agents were considered together (RR 2.88, 95% CI 1.06 to 7.80; 1 study, 500 participants; I<sup>2</sup> = 0%, very low‐certainty evidence; <a href="./references#CD012369-fig-0008" title="">Analysis 1.5</a>). We performed a subgroup analysis by grouping the results by type of antiplatelet agents as we did in the PTS outcome above (<a href="./references#CD012369-fig-0009" title="">Analysis 1.6</a>). There was no evidence of a difference in the risk of adverse events between antiplatelet plus BMP and the control groups when we grouped piracetam and buflomedil together, again without important heterogeneity (RR 1.00, 95% CI 0.22 to 4.56; 1 study, 250 participants; I<sup>2</sup> = 0%; very low‐certainty evidence). However, there was a difference in favour of the control group when compared with the combined pentoxifylline and dipyridamole groups, without important heterogeneity (RR 4.75, 95% CI 1.19 to 19.03; 1 study, 250 participants; I<sup>2</sup> = 0%; very low‐certainty evidence). Statistical tests for subgroup differences revealed no clear difference between groups (P = 0.14). </p> </section> <section id="CD012369-sec-0067"> <h6 class="title">Quality of life (QoL)</h6> <p>There were no available data for this outcome.</p> </section> <section id="CD012369-sec-0068"> <h6 class="title">Duration of hospitalisation</h6> <p>There were no available data for this outcome.</p> </section> </section> </section> <section id="CD012369-sec-0069"> <h4 class="title">Chronic DVT ‐ antiplatelet agents plus BMP versus BMP alone</h4> <p>One included study evaluated this comparison (<a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>). </p> <section id="CD012369-sec-0070"> <h5 class="title">Primary outcomes</h5> <section id="CD012369-sec-0071"> <h6 class="title">Recurrent VTE</h6> <p><a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> did not describe PE or VTE, so data for recurrent VTE only include the reported data of recurrent DVT at 3 years of follow‐up (intermediate time). <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> demonstrated a lower risk of recurrent VTE in the antiplatelet agents plus BMP group (RR 0.12, 95% CI 0.05 to 0.34; 1 study, 224 participants; very low‐certainty evidence; <a href="./references#CD012369-fig-0010" title="">Analysis 2.1</a>). We also evaluated the data by subgroups with and without compression stockings (<a href="./references#CD012369-fig-0010" title="">Analysis 2.1</a>), as planned in the protocol of this review (<a href="./references#CD012369-bbs2-0087" title="FlumignanCD , FlumignanRL , Baptista-SilvaJC . Antiplatelet agents for the treatment of deep venous thrombosis. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012369. [DOI: 10.1002/14651858.CD012369]">Flumignan 2016</a>). In the subgroup without compression stockings, the participants receiving antiplatelet agents plus BMP had a lower risk of recurrent VTE than the control group (RR 0.11, 95% CI 0.03 to 0.34; 1 study, 123 participants; very low‐certainty evidence). However, in the subgroup with compression stockings, there was no clear difference between the antiplatelet agents plus BMP and control groups (RR 0.22, 95% CI 0.03 to 1.82; 1 study, 101 participants; very low‐certainty evidence). Statistical tests for subgroup differences did not reveal a clear difference between groups (P = 0.56). </p> </section> <section id="CD012369-sec-0072"> <h6 class="title">Major bleeding</h6> <p>We could not estimate the effect of antiplatelet agents for major bleeding because the study authors reported no side effects during the 3 years of follow‐up (zero events) (<a href="./references#CD012369-fig-0011" title="">Analysis 2.2</a>). </p> </section> <section id="CD012369-sec-0073"> <h6 class="title">PE (fatal/nonfatal)</h6> <p>Although the study authors reported no dropout for PE, the outcome was not a preplanned outcome, and it was not reported in the results. Therefore, we could not estimate the effect of the interventions with the available data. </p> </section> </section> <section id="CD012369-sec-0074"> <h5 class="title">Secondary outcomes</h5> <section id="CD012369-sec-0075"> <h6 class="title">Mortality</h6> <p>We could not estimate this effect with the available data because the study authors reported zero cases of death during 3 years of follow‐up (<a href="./references#CD012369-fig-0012" title="">Analysis 2.3</a>). </p> </section> <section id="CD012369-sec-0076"> <h6 class="title">PTS</h6> <p>There were no available data for this outcome.</p> </section> <section id="CD012369-sec-0077"> <h6 class="title">Adverse events</h6> <p>We could not estimate this effect with the available data (zero events) (<a href="./references#CD012369-fig-0013" title="">Analysis 2.4</a>). </p> </section> <section id="CD012369-sec-0078"> <h6 class="title">QoL</h6> <p>There were no available data for this outcome.</p> </section> <section id="CD012369-sec-0079"> <h6 class="title">Duration of hospitalisation</h6> <p>There were no available data for this outcome.</p> </section> </section> </section> <section id="CD012369-sec-0080"> <h4 class="title">Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo</h4> <p>Four included studies contributes data for this comparison (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>; <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>; <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>). </p> <section id="CD012369-sec-0081"> <h5 class="title">Primary outcomes</h5> <section id="CD012369-sec-0082"> <h6 class="title">Recurrent VTE</h6> <p>All four studies (<a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> at 18 months, <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> at 3 months, <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> at 24 months, and <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> with a median follow‐up of 37.2 months) had available data for this outcome; meta‐analysis of this data showed a lower risk of recurrent VTE for the antiplatelet agents group compared with the control group (RR 0.65, 95%, CI 0.43 to 0.96; 4 studies, 901 participants; NNTB = 14; low‐certainty evidence; <a href="./references#CD012369-fig-0014" title="">Analysis 3.1</a>). We deemed heterogeneity for the overall effect viewed in <a href="./references#CD012369-fig-0014" title="">Analysis 3.1</a> as not important (I<sup>2</sup> = 19%). </p> <p>When analysed by antiplatelet subgroups, the antiplatelet arms achieved a lower risk of recurrent VTE for the acetylsalicylic acid (ASA) subgroup (RR 0.71, 95% CI 0.53 to 0.97; 2 studies, 835 participants; NNTB = 18; low‐certainty evidence), but this was not seen in the sulfinpyrazone group (RR 0.14, 95% CI 0.01 to 2.53; 1 study, 28 participants; low‐certainty evidence) nor in the ASA plus dipyridamole group (RR 0.14, 95% CI 0.02 to 1.05; 1 study, 38 participants; low‐certainty evidence) (<a href="./references#CD012369-fig-0014" title="">Analysis 3.1</a>). Statistical tests for subgroup differences did not reveal a clear difference between subgroups (P = 0.17). </p> </section> <section id="CD012369-sec-0083"> <h6 class="title">Major bleeding</h6> <p>Major bleeding was a prespecified safety outcome in <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>, but their data were not available for the participants with confirmed DVT separately from those with only PE. We could therefore not include the <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> data in the analysis. <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> and <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> did not specifically report this outcome. </p> <p>In <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>, this outcome was prespecified and reported. Major bleeding is defined as a minimum of 2 g/dL decreased haemoglobin, intracranial and/or retroperitoneal bleeding, haemorrhagic events with death outcome, transfusion a minimum of two units of blood. These definitions were based on the International Society on Thrombosis and Haemostasis (ISTH) (<a href="./references#CD012369-bbs2-0071" title="SchulmanS , KearonC . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4. [PMID: 15842354]">Schulman 2005</a>). The analysis showed no clear difference between BMP plus placebo and antiplatelet agents plus BMP groups (RR 0.98, 95% CI 0.29 to 3.34; 1 study, 583 participants; moderate‐certainty evidence; <a href="./references#CD012369-fig-0015" title="">Analysis 3.2</a>) </p> </section> <section id="CD012369-sec-0084"> <h6 class="title">PE (fatal/nonfatal)</h6> <p><a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> did not provide isolated information about PE from participants with DVT or with DVT plus PE as the index event. <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> reported 3.2% PE events after 24.5 months of follow‐up in the subgroup of DVT as index event, but, in the study report, it is not clear if the group with DVT plus PE is included in this presented data. Because of this, we did not utilise the data in this review's meta‐analysis. </p> <p>PE was not a preplanned outcome for <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>, but the study authors mentioned one event of pulmonary infarction in the control group. Since the number of events in the intervention group was not mentioned, we could not use the overall data in this review. PE was cited as a previous disease before randomisation in <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>, but PE was not a preplanned outcome, and it was not mentioned in the results. </p> <p><a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> provided data about the group of interest for this review, describing the outcome as PE confirmed by computed tomography pulmonary angiography (CTPA) or ventilation/perfusion (V/Q) scan, or both. Results showed no clear difference between the treatment groups (RR 0.52, 95% CI 0.23 to 1.14; 1 study, 583 participants; moderate‐certainty evidence; <a href="./references#CD012369-fig-0016" title="">Analysis 3.3</a>). </p> </section> </section> <section id="CD012369-sec-0085"> <h5 class="title">Secondary outcomes</h5> <section id="CD012369-sec-0086"> <h6 class="title">Mortality</h6> <p><a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> reported no deaths during 18 months of follow‐up. <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> presented separate subgroups (all‐cause and VTE‐related), during a median follow‐up of 37.2 months. In the all‐cause mortality group, it presented a greater number of events in the placebo group, compared with intervention group (16 events of 288 participants in the placebo group, and 8 events of 295 participants in the antiplatelet agent group). In the VTE‐related mortality group, one death occurred in the placebo group. Although <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> provided details about mortality in their different groups, we could not extract any relevant data of participants with the index event of DVT. <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> had data regarding mortality at 3 months of follow‐up, which could be used in this comparison. The overall effect of antiplatelet agents did not differ from the placebo in the all‐cause mortality subgroup, without important heterogeneity (RR 0.48, 95% CI 0.21 to 1.06; 3 studies, 649 participants; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD012369-fig-0017" title="">Analysis 3.4</a>). In the VTE‐related mortality subgroup, including data from one study (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>), we found no clear difference between antiplatelet agents plus BMP group and placebo plus BMP group (RR 0.33, 95% CI 0.01 to 7.96; 1 study, 583 participants; moderate‐certainty evidence; <a href="./references#CD012369-fig-0017" title="">Analysis 3.4</a>). </p> </section> <section id="CD012369-sec-0087"> <h6 class="title">Post‐thrombotic syndrome</h6> <p>None of the included studies provided data for this outcome.</p> </section> <section id="CD012369-sec-0088"> <h6 class="title">Adverse events</h6> <p><a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a> reported two participants with peptic ulcers and another participant with epigastric pain in the intervention group during 18 months of follow‐up. They reported no adverse events in the control group. <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> reported six participants with minor bleeds (2 in control group and 4 in the antiplatelet group), 16 participants had respiratory adverse events (8 in the control group and 8 in the antiplatelet group), and 26 participants had adverse events of the gastrointestinal tract (13 in the control group and 13 in the antiplatelet group). <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> reported two adverse events in the control group, and no adverse events in the intervention group but did not describe the adverse events. <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> did not provide sufficient details about this data because of the limitations already described. The effect estimate of this outcome showed no clear difference between the antiplatelet agents plus BMP and the placebo plus BMP groups when all adverse events were pooled together, with moderate heterogeneity (RR 1.57, 95% CI 0.34 to 7.19; 2 studies, 621 participants; I<sup>2</sup> = 38%; moderate‐certainty evidence; <a href="./references#CD012369-fig-0018" title="">Analysis 3.5</a>). Similarly, when each subgroup is analysed, no clear difference was shown: gastrointestinal adverse events (RR 1.58, 95% CI 0.29 to 8.49; 2 studies, 621 participants); respiratory adverse events (RR 0.98, 95% CI 0.37 to 2.57; 1 study, 583 participants); and minor bleeds (RR 1.95, 95% CI 0.36 to 10.58; 1 study, 583 participants; <a href="./references#CD012369-fig-0018" title="">Analysis 3.5</a>). </p> </section> <section id="CD012369-sec-0089"> <h6 class="title">QoL</h6> <p>There were no available data for this outcome.</p> </section> <section id="CD012369-sec-0090"> <h6 class="title">Duration of hospitalisation</h6> <p>Only <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> provided data about duration of hospitalisation, in days (hospitalised participants: ASA = 69, control = 89). The results showed no clear difference between the antiplatelet agents plus BMP and the placebo plus BMP groups (MD ‐2.10 days, 95% CI ‐9.29 to 5.09; 1 study, 158 participants; moderate‐certainty evidence; <a href="./references#CD012369-fig-0019" title="">Analysis 3.6</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012369-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012369-sec-0091"></div> <section id="CD012369-sec-0092"> <h3 class="title" id="CD012369-sec-0092">Summary of main results</h3> <p>VTE is the third most common cardiovascular disease in the world and is a growing public health problem, largely due to an ageing population (<a href="./references#CD012369-bbs2-0037" title="GoldhaberSZ . Venous thromboembolism: epidemiology and magnitude of the problem. Best Practice and Research. Clinical Haematology2012;25(3):235-42. [PMID: 22959540]">Goldhaber 2012</a>; <a href="./references#CD012369-bbs2-0080" title="TagalakisV , PatenaudeV , KahnSR , SuissaS . Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE study cohort. American Journal of Medicine2013;126(9):832.e13-21. [PMID: 23830539]">Tagalakis 2013</a>). Platelets are the principal effector cells for haemostasis, coagulation and thrombosis that are unique to mammals, and are therefore deeply related to thrombus formation in DVT (<a href="./references#CD012369-bbs2-0085" title="Vieira-de-AbreuA , CampbellRA , WeyrichAS , ZimmermanGA . Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Seminars in Immunopathology2012;34(1):5-30. [PMID: 21818701]">Vieira‐de‐Abreu 2012</a>). Because antiplatelet agents act in Virchow’s triad as inhibitors of clot formation, they may be a complement to the current treatment for DVT. </p> <p>We identified three possible comparisons with the data of the included studies: 1) acute DVT ‐ antiplatelet agents plus BMP versus BMP alone, 2) chronic DVT ‐ antiplatelet agents plus BMP versus BMP alone, and 3) chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo. </p> <section id="CD012369-sec-0093"> <h4 class="title">Acute DVT</h4> <p>In a setting of acute DVT, antiplatelet agents plus BMP versus BMP alone was compared in one study (<a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>). <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> reported four of our relevant outcomes during 6 months of follow‐up (early time point; major bleeding, mortality, post‐thrombotic syndrome (PTS) and adverse events). At the early time point, there were no deaths and no cases of major bleeding reported. The participants that received antiplatelet agents seemed to have a lower risk of PTS (early time point), but the evidence was of very low certainty. The control group had a lower risk of adverse events compared to the intervention group. The results from <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> should be viewed with caution, because the study had at least four of the seven risk of bias domains classed as high risk of bias. For instance, there was no blinding of participants and personnel, no details about loss and dropout of participants, no report about PE, and we suspected pharmaceutical company support, although not clearly mentioned in the report. </p> </section> <section id="CD012369-sec-0094"> <h4 class="title">Chronic DVT</h4> <p>In a setting of chronic DVT where the antiplatelet agents plus BMP were compared with BMP alone, we also identified one study (<a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>). Despite the study authors reporting four of our relevant outcomes (recurrent VTE, major bleeding, mortality and adverse events), three of them (major bleeding, mortality and adverse events) did not have any events during the 3 years of follow‐up (intermediate time point). Thus, we could only report an effect estimate for recurrent VTE. The effect estimate appeared to be in favour of antiplatelet agents, but the evidence was of very low certainty. The results from <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> should be viewed with caution, because the study had at least four of the seven risk of bias domains classed as high risk of bias. For instance, there was no blinding of participants and personnel, no details about the loss and dropout participants, and suspicions of duplicate publication without clear mention in the report. </p> <p>In a setting of chronic DVT where the antiplatelet agents plus BMP are compared with BMP plus placebo, we included four RCTs which provided information about six of our relevant outcomes: recurrent VTE, major bleeding, PE fatal/nonfatal, mortality, adverse events and duration of hospitalisation (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>; <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>; <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>). </p> <p>The meta‐analysis showed a lower risk of recurrent VTE for early to long‐term time points, but the evidence was of low certainty. <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> provided data about major bleeding, showing no clear difference between placebo and antiplatelets (moderate‐certainty evidence). The other studies did not provide major bleeding data that could be used in this review. <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> was also the only study with data for the PE fatal/nonfatal outcome showing no clear difference between placebo and antiplatelet groups, also with evidence of moderate certainty. </p> <p>Two studies provided information about all‐cause mortality up to 37.2 months of follow‐up (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>), showing no clear difference between antiplatelet agents and placebo (moderate‐certainty evidence). VTE‐related mortality, with available data from <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>, showed no clear difference between the antiplatelet agent group and placebo (moderate‐certainty evidence). Two studies described adverse events (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>; <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>), with no clear difference between antiplatelet agent and placebo groups (moderate‐certainty evidence). </p> <p>Duration of hospitalisation was reported by <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>, without a clear difference between antiplatelet and placebo groups (moderate‐certainty evidence). </p> </section> </section> <section id="CD012369-sec-0095"> <h3 class="title" id="CD012369-sec-0095">Overall completeness and applicability of evidence</h3> <p>This review assessed whether the addition of antiplatelet agents to BMP for the treatment of DVT could reduce recurrent VTE in a safe manner without major bleeding or PE. It also evaluated other relevant parameters such as mortality, PTS, adverse events, QoL, and time of hospitalisation. </p> <p>The overall evidence was based on six studies involving 1625 eligible participants in the USA, Canada, many countries in Europe, India, Argentina, Australia and New Zealand. </p> <p>We found one study for each comparison with BMP as the control group (without placebo). <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> (500 participants) evaluated the effects of antiplatelet agents in acute DVT concomitant with the anticoagulant therapy; <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> (224 participants) evaluated the same comparison in a setting of chronic DVT after the interruption of initial anticoagulant therapy. The four other studies, with a total of 901 participants, that could be included in this review (38 in <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>, 28 in <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>, 252 in <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> and 583 in <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>) evaluated the effects of antiplatelet agents as additional intervention compared with BMP plus placebo, in a setting of chronic DVT. All included studies evaluated at least one of our primary outcomes (major bleeding in <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>; recurrent VTE and major bleeding in <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>; recurrent VTE in <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>, <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> and <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>; and recurrent VTE, major bleeding and PE fatal/nonfatal in <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>). Also, the included studies reported on at least one of our secondary outcomes (mortality, PTS and adverse events in <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>; mortality and adverse events in <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>, <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>, <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> and <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>; and mortality (divided between VTE‐related and all‐cause), adverse events and duration of hospitalisation in <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>), but there was a lack of mortality events in <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a> and <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> and a lack of adverse events in <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>. </p> <p><a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> had only a portion of data analysed in this review: study data were not stratified by participants with DVT and PE for all outcomes. Our efforts to contact the authors to obtain this data were not successful. We classified only one included study as low risk of bias (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>), and our efforts to contact the authors to obtain additional data were successful. </p> <p>We did not identify studies comparing antiplatelet agents plus BMP versus BMP plus placebo for acute DVT. </p> <p>The key limitations of this review are:</p> <p> <ul id="CD012369-list-0017"> <li> <p>some of the included studies presented a high risk of bias (<a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>; <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>; <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>); </p> </li> <li> <p>the lack of QoL data;</p> </li> <li> <p>some data were not available. We did not have access to all of the <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> data of interest for this review stratified by the index event (confirmed DVT). Therefore, there were no data regarding major bleeding, PE fatal/non‐fatal, mortality, adverse events and duration of hospitalisation from the <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> study included in this review; </p> </li> <li> <p>short length of follow‐up (from 3 months to 37 months);</p> </li> <li> <p>age of included studies (from 1978 to 2012).</p> </li> </ul> </p> <p>With the evaluation of all available data, the resulting analysis found low‐certainty evidence to support the use of antiplatelet agents for the treatment of chronic DVT in early, intermediate and long‐term follow‐up, for the reduction of recurrent VTE. However, these results should be viewed with caution, because all other evidence from this review had very low‐ to moderate‐certainty evidence for important outcomes such as major bleeding. Future high‐certainty studies may change the results of all available data. </p> <p>The short length of follow‐up (from 3 months to 37 months) limited our analysis for the long‐term time point and impacted data for chronic complications of DVT, such as PTS. All included studies were conducted and published more than 10 years ago (from 1978 to 2012) and there have been some changes in what is considered BMP for the treatment of DVT episodes. For instance, recommendations for home treatment and early de‐ambulation for people with acute DVT were not present at the time of those included studies, but are present in the most recent guidelines (<a href="./references#CD012369-bbs2-0049" title="KakkosSK , GohelM , BaekgaardN , BauersachsR , Bellmunt-MontoyaS , BlackSA , et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the management of venous thrombosis. European Journal of Vacular and Endovascular Surgery2021;61(1):9-82. [PMID: 10.1016/j.ejvs.2020.09.023]">Kakkos 2021</a>; <a href="./references#CD012369-bbs2-0079" title="StevensSM , WollerSC , KreuzigerLB , BounameauxH , DoerschugK , GeersingGJ , et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):e545-608. [DOI: 10.1016/j.chest.2021.07.055]">Stevens 2021</a>). In the most recent era, another important VTE risk factor, the SARS‐CoV‐2 virus, presents a global issue that was not addressed in the included studies (<a href="./references#CD012369-bbs2-0028" title="COVIDSurg Collaborative, GlobalSurg Collaborative. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. Anaesthesia2022;77(1):28-39. [PMID: 10.1111/anae.15563]">COVIDSurg 2022</a>; <a href="./references#CD012369-bbs2-0035" title="FlumignanRL , CivileVT , TinôcoJD , PascoalPI , AreiasLL , MatarCF , et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD013739. [DOI: 10.1002/14651858.CD013739.pub2]">Flumignan 2022</a>; <a href="./references#CD012369-bbs2-0069" title="SantosBC , FlumignanRL , CivileVT , AtallahAN , NakanoLC . Prophylactic anticoagulants for non-hospitalised people with COVID-19. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015102. [DOI: 10.1002/14651858.CD015102]">Santos 2022</a>). </p> <p>We intended to include the utilisation of an IVC filter, but in this review we did not find such separate data. In future versions, if we find any data utilising the IVC filter, we will consider this in a subgroup analysis. </p> </section> <section id="CD012369-sec-0096"> <h3 class="title" id="CD012369-sec-0096">Certainty of the evidence</h3> <p>We created a summary of findings table for each comparison with <a href="./references#CD012369-bbs2-0039" title="McMaster University (developed by Evidence Prime)GRADEpro GDT Guideline Development Tool. Version accessed 6 March 2018. Hamilton (OH): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a> software. </p> <p>For the comparison of antiplatelet agents plus BMP versus BMP for the treatment of acute DVT (<a href="./full#CD012369-tbl-0001">summary of findings Table 1</a>), we found very low‐certainty evidence for the included study (<a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>). We could not assess the effect of the intervention for major bleeding and mortality because there were no events during the 6 months of follow‐up. We downgraded the certainty of the evidence by two levels because of a high risk of bias due to lack of a placebo in the control group and lack of blinding for participants and personnel. The study authors also did not report losses and exclusions and did not mention embolisation, one of the study’s prespecified outcomes that we tried to evaluate in this review. The full protocol was not available, and we suspected pharmaceutical company support, although not clearly mentioned in the report. Following GRADE recommendations we did not downgrade for inconsistency because there was only one study. However, we downgraded a half level for imprecision as there were fewer than 300 events included in the analysis. We downgraded by one level for indirectness because the study authors did not explain the criteria for major bleeding, instead only citing that "severe bleedings were absent, in every group". We downgraded a half level for indirectness because of the assessment of PTS using a non‐validated method. </p> <p><a href="./full#CD012369-tbl-0002">summary of findings Table 2</a> shows the certainty of evidence for the comparison of antiplatelet agents plus BMP versus BMP without placebo for the treatment of chronic DVT. We found very low‐certainty evidence for all outcomes up to 3 years of follow‐up. The single study in this comparison demonstrated a high risk of bias (which was a large contributor to the low certainty of the evidence (<a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>). We downgraded all reported outcomes by two levels in the risk of bias domain because the control group did not have an oral treatment, there was no blinding of participants and personnel during the study and the dropouts were not cited in detail. In addition, the full protocol of the study was not available. The study authors did not describe PE, which was the study’s prespecified outcome. Following GRADE recommendations we did not downgrade for inconsistency because there was only one study. We downgraded by one level because of indirectness as there was not a clear definition of major bleeding. We downgraded a half level due to imprecision as there were fewer than 300 events included in the analysis. We downgraded further as we suspected duplicate publication. </p> <p><a href="./full#CD012369-tbl-0003">summary of findings Table 3</a> shows the certainty of evidence for the comparison of antiplatelet agents plus BMP versus BMP plus placebo for the treatment of chronic DVT, using the data of four studies (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>; <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>; <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>). We found low‐certainty evidence suggesting that the participants that received ASA and BMP as treatment had a lower risk of recurrent VTE in early, intermediate and long‐term follow‐up after randomisation. <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> presented, in the 'historical versions' available in ClinicalTrials.gov, changes in its primary and secondary outcomes near publication date of the study, and we classified this as high risk of selective reporting bias. <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> included one group treated with warfarin, after randomisation. Moreover, the investigators used different anticoagulation treatments (warfarin or heparin) for some participants, and this was not sufficiently described. There were no details of numbers of anticoagulated participants in each group. Combined, these limitations resulted in us downgrading by one level for risk of bias. We judged PE, major bleeding events, mortality and adverse events as moderate‐certainty evidence. We downgraded the certainty of evidence a half level due to imprecision (fewer than 300 events were included in the analysis) for these outcomes. </p> <p>The risk of bias differed substantially among the studies (<a href="#CD012369-fig-0002">Figure 2</a> and <a href="#CD012369-fig-0003">Figure 3</a>), and it substantially affected the overall certainty of the evidence. The high risk of bias of some of the included studies was deeply correlated to a lack of information in the reporting of the study results. The absence of a prior protocol for the randomised trials and the lack of response from the study authors in order to reduce inconsistencies and queries about methodology are examples of this knowledge gap. It was also reflected by the evidence, because all results from the first two comparisons were deemed to be of very low certainty. All of the results from this very low‐certainty evidence (comparisons without a placebo control (comparisons 1 and 2)) had similar problems of methodology; for example, they did not blind participants or personnel during the studies. This very low‐certainty evidence means that we have very little confidence in the effect estimate, because the true effect is likely to be substantially different from the estimate of effect. We have to note that, it is likely that future versions of this review will not include additional RCTs in comparisons 1 and 2 that did not use a placebo control, as it is expected that new RCTs will have more adequate study designs, with more careful protocols regarding methodology. The use of rigorous methodology and a placebo control is expected in most RCTs, especially in a pharmacological intervention. The use of a placebo medication in a control group with the same features of the intervention drug is important to guarantee blinding of participants and personnel. Since a placebo control is feasible and adds great credence to the results, we hope to find only new RCTs with a placebo or other active drug control. </p> </section> <section id="CD012369-sec-0097"> <h3 class="title" id="CD012369-sec-0097">Potential biases in the review process</h3> <p>We believe that we identified and included all relevant RCTs using a search methodology that included multiple sources, without language restriction, date or status of publication. When duplicate reports of studies were identified during the selection process, we managed to utilise the best information. </p> <p>We requested relevant data from study authors, but only one responded to our questions. We strictly observed the criteria described in the protocol to include or exclude participants in order to limit any kind of non‐compliance with the protocol (<a href="./references#CD012369-bbs2-0087" title="FlumignanCD , FlumignanRL , Baptista-SilvaJC . Antiplatelet agents for the treatment of deep venous thrombosis. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012369. [DOI: 10.1002/14651858.CD012369]">Flumignan 2016</a>). </p> <p>We performed double‐data extraction with the goal of reducing bias in the review process and ensuring the quality of assessment of included RCTs. </p> <p>In some of the included studies, we only included a portion of the participants. For instance, we did not include the 'without treatment' group in <a href="./references#CD012369-bbs2-0011" title="MoriauM , Col-De BeysC , PardongeE , FerrantA . Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.). Thrombosis and Haemostasis1982;47(1):27-31. [PMID: 6280332]">Moriau 1982</a> because the lack of anticoagulant treatment is not currently acceptable BMP. For <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>, we could only include data for the outcome 'recurrence of VTE' (252 of 403), as this was the only outcome for which we stratified by the study population of interest for this review (participants with DVT with or without PE). The <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> trial team provided us separate data for the group with DVT with or without PE, making it feasible to use their results. </p> <p>In addition, for <a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a> we had suspicions of duplicate publication of the same data, although not clearly mentioned in the relevant publications. We tried to contact the study authors without success. Therefore, we analysed both reports as the same study. </p> <p>We did not perform a funnel plot assessment because of the insufficient number of included studies (less than 10) in each comparison. </p> </section> <section id="CD012369-sec-0098"> <h3 class="title" id="CD012369-sec-0098">Agreements and disagreements with other studies or reviews</h3> <p>We did not find another systematic review of RCTs assessing the effects of antiplatelet agents for the treatment of DVT. There are three systematic reviews that assessed the effects of anticoagulant and antiplatelet interventions for the treatment and for the secondary prevention of VTE (<a href="./references#CD012369-bbs2-0026" title="CastellucciLA , CameronC , Le GalG , RodgerMA , CoyleD , WellsPS , et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ (Clinical research ed.)2013;347:f5133. [PMID: 23996149]">Castellucci 2013</a>; <a href="./references#CD012369-bbs2-0053" title="MarikPE , CavallazziR . Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and meta-analysis. PloS one2015;10(11):e0143252. [PMID: 26587983]">Marik 2015</a>; <a href="./references#CD012369-bbs2-0077" title="SobierajDM , ColemanCI , PasupuletiV , DeshpandeA , KawR , HernandezAV . Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis. Thrombosis Research2015;135(5):888-96. [PMID: 25795564]">Sobieraj 2015</a>). These reviews evaluated anticoagulants and antiplatelet agents together and at different time points of the treatment, mainly for the long‐term treatment of DVT. Our review evaluated only the effects of antiplatelet agents for the treatment of DVT. The unique difference among the comparison groups in our review was the presence or absence of antiplatelet agents (<a href="./references#CD012369-bbs2-0087" title="FlumignanCD , FlumignanRL , Baptista-SilvaJC . Antiplatelet agents for the treatment of deep venous thrombosis. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012369. [DOI: 10.1002/14651858.CD012369]">Flumignan 2016</a>). There are other essential differences in each identified systematic review that evaluated the treatment of VTE, i.e. they included participants with only PE or with unconfirmed DVT, while in our review we included only participants with confirmed DVT. </p> <p><a href="./references#CD012369-bbs2-0077" title="SobierajDM , ColemanCI , PasupuletiV , DeshpandeA , KawR , HernandezAV . Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis. Thrombosis Research2015;135(5):888-96. [PMID: 25795564]">Sobieraj 2015</a> presented a comparison with antiplatelet agents and anticoagulants (VKA and direct oral anticoagulants (DOACs)). Their review also assessed the results from anticoagulants in comparison to antiplatelet agents or a placebo, which is a major difference from our review that did not analyse anticoagulants. <a href="./references#CD012369-bbs2-0077" title="SobierajDM , ColemanCI , PasupuletiV , DeshpandeA , KawR , HernandezAV . Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis. Thrombosis Research2015;135(5):888-96. [PMID: 25795564]">Sobieraj 2015</a> did not include some studies that are in our review (<a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>; <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>; <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>), and excluded 27 citations without reporting the reasons for exclusion. However, they did include two of our included studies (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> and <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>). <a href="./references#CD012369-bbs2-0077" title="SobierajDM , ColemanCI , PasupuletiV , DeshpandeA , KawR , HernandezAV . Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis. Thrombosis Research2015;135(5):888-96. [PMID: 25795564]">Sobieraj 2015</a> analysed the data from <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> because they evaluated VTE and not just DVT as our review did. Although one of the search strategies was presented in the appendix of the <a href="./references#CD012369-bbs2-0077" title="SobierajDM , ColemanCI , PasupuletiV , DeshpandeA , KawR , HernandezAV . Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis. Thrombosis Research2015;135(5):888-96. [PMID: 25795564]">Sobieraj 2015</a> report, there was no mention of language restrictions in the text, and we did not have access to the protocol of the <a href="./references#CD012369-bbs2-0077" title="SobierajDM , ColemanCI , PasupuletiV , DeshpandeA , KawR , HernandezAV . Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis. Thrombosis Research2015;135(5):888-96. [PMID: 25795564]">Sobieraj 2015</a> review or to the registration number in the <a href="https://www.crd.york.ac.uk/PROSPERO/" target="_blank">PROSPERO</a> database for clarification. </p> <p><a href="./references#CD012369-bbs2-0026" title="CastellucciLA , CameronC , Le GalG , RodgerMA , CoyleD , WellsPS , et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ (Clinical research ed.)2013;347:f5133. [PMID: 23996149]">Castellucci 2013</a> was similar to our review because they provided data of prospective research with a registry number in a database of systematic reviews (<a href="https://www.crd.york.ac.uk/PROSPERO/" target="_blank">PROSPERO</a>), with no limits for language, data or status of publication. However, they evaluated a smaller number of databases (MEDLINE, Embase and CENTRAL) than our review. As well as antiplatelet agents, <a href="./references#CD012369-bbs2-0026" title="CastellucciLA , CameronC , Le GalG , RodgerMA , CoyleD , WellsPS , et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ (Clinical research ed.)2013;347:f5133. [PMID: 23996149]">Castellucci 2013</a> also evaluated anticoagulants for VTE. They analysed two of our included RCTs (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> and <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>), but they did not evaluate four of our included studies (<a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>; <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>; <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>). </p> <p><a href="./references#CD012369-bbs2-0053" title="MarikPE , CavallazziR . Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and meta-analysis. PloS one2015;10(11):e0143252. [PMID: 26587983]">Marik 2015</a> also had similarities to our review because they reported no limits for language, data or status of publication and followed a guideline proposed by the PRISMA group (<a href="./references#CD012369-bbs2-0051" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ2009;339:b2700. [DOI: 10.1136/bmj.b2700]">Liberati 2009</a>; <a href="./references#CD012369-bbs2-0057" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ2009;339:b2535. [DOI: 10.1136/bmj.b2535]">Moher 2009</a>), although there is no registration number or an available protocol for the review. <a href="./references#CD012369-bbs2-0053" title="MarikPE , CavallazziR . Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and meta-analysis. PloS one2015;10(11):e0143252. [PMID: 26587983]">Marik 2015</a> was somewhat more restrictive than the <a href="./references#CD012369-bbs2-0026" title="CastellucciLA , CameronC , Le GalG , RodgerMA , CoyleD , WellsPS , et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ (Clinical research ed.)2013;347:f5133. [PMID: 23996149]">Castellucci 2013</a> and <a href="./references#CD012369-bbs2-0077" title="SobierajDM , ColemanCI , PasupuletiV , DeshpandeA , KawR , HernandezAV . Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis. Thrombosis Research2015;135(5):888-96. [PMID: 25795564]">Sobieraj 2015</a> reviews, because <a href="./references#CD012369-bbs2-0053" title="MarikPE , CavallazziR . Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and meta-analysis. PloS one2015;10(11):e0143252. [PMID: 26587983]">Marik 2015</a> studied the use of aspirin and oral anticoagulants (VKA and DOACs) for the secondary prevention of VTE. <a href="./references#CD012369-bbs2-0053" title="MarikPE , CavallazziR . Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and meta-analysis. PloS one2015;10(11):e0143252. [PMID: 26587983]">Marik 2015</a> deliberately did not seek other types of antiplatelet agents. They were also more restrictive in their database search because they considered only MEDLINE and CENTRAL. This restrictive criteria reflects on the included studies, because they evaluated <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> and <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> and did not evaluate four of our included studies (<a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>; <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>; <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>). </p> <p>Even though <a href="./references#CD012369-bbs2-0026" title="CastellucciLA , CameronC , Le GalG , RodgerMA , CoyleD , WellsPS , et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ (Clinical research ed.)2013;347:f5133. [PMID: 23996149]">Castellucci 2013</a>, <a href="./references#CD012369-bbs2-0053" title="MarikPE , CavallazziR . Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and meta-analysis. PloS one2015;10(11):e0143252. [PMID: 26587983]">Marik 2015</a> and <a href="./references#CD012369-bbs2-0077" title="SobierajDM , ColemanCI , PasupuletiV , DeshpandeA , KawR , HernandezAV . Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis. Thrombosis Research2015;135(5):888-96. [PMID: 25795564]">Sobieraj 2015</a> evaluated the same two RCTs with antiplatelet agents in the intervention group (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>; <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>), those reviews presented substantial differences in their effect estimates. <a href="./references#CD012369-bbs2-0026" title="CastellucciLA , CameronC , Le GalG , RodgerMA , CoyleD , WellsPS , et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ (Clinical research ed.)2013;347:f5133. [PMID: 23996149]">Castellucci 2013</a> and <a href="./references#CD012369-bbs2-0053" title="MarikPE , CavallazziR . Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and meta-analysis. PloS one2015;10(11):e0143252. [PMID: 26587983]">Marik 2015</a> reported a significant reduction in VTE risk, but <a href="./references#CD012369-bbs2-0077" title="SobierajDM , ColemanCI , PasupuletiV , DeshpandeA , KawR , HernandezAV . Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis. Thrombosis Research2015;135(5):888-96. [PMID: 25795564]">Sobieraj 2015</a> did not report a significant decrease of recurrent VTE risk when aspirin was compared to placebo. The use of indirect statistical analysis (network meta‐analysis) and random‐effect model for all meta‐analyses may have influenced the different effect estimates. Our review, meanwhile, used a direct meta‐analysis with a random or fixed‐effect model for comparisons depending on the studies' heterogeneity (<a href="./references#CD012369-fig-0014" title="">Analysis 3.1</a>; <a href="./references#CD012369-fig-0018" title="">Analysis 3.5</a>). </p> <p><a href="./references#CD012369-bbs2-0076" title="SimesJ , BecattiniC , AgnelliG , EikelboomJW , KirbyAC , MisterR , et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation2014;130(13):1062-71. [PMID: 25156992]">Simes 2014</a> made a prospective compilation (INSPIRE) of two primary RCTs (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>; <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>), with a meta‐analysis of data but without a search strategy and without the intention to perform a systematic review. Therefore, we treated the <a href="./references#CD012369-bbs2-0076" title="SimesJ , BecattiniC , AgnelliG , EikelboomJW , KirbyAC , MisterR , et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation2014;130(13):1062-71. [PMID: 25156992]">Simes 2014</a> report as a narrative review with a meta‐analysis of two RCTs. <a href="./references#CD012369-bbs2-0076" title="SimesJ , BecattiniC , AgnelliG , EikelboomJW , KirbyAC , MisterR , et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation2014;130(13):1062-71. [PMID: 25156992]">Simes 2014</a> ascertained that aspirin may reduce the risk of recurrent VTE in participants with VTE after the conclusion of initial treatment with anticoagulants with stronger evidence than the isolated RCTs (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>; <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>). <a href="./references#CD012369-bbs2-0076" title="SimesJ , BecattiniC , AgnelliG , EikelboomJW , KirbyAC , MisterR , et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation2014;130(13):1062-71. [PMID: 25156992]">Simes 2014</a> also concluded that the antiplatelet agent used did not add any risk of bleeding until more than 24 months of follow‐up. Since <a href="./references#CD012369-bbs2-0076" title="SimesJ , BecattiniC , AgnelliG , EikelboomJW , KirbyAC , MisterR , et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation2014;130(13):1062-71. [PMID: 25156992]">Simes 2014</a> evaluated participants with only PE at randomisation time, we cannot directly compare their results with ours. </p> <p>There are also a number of narrative reviews addressing the use of antiplatelet agents for the treatment and prevention of VTE but not solely DVT (<a href="./references#CD012369-bbs2-0016" title="AutarR . Evidence for the prevention of venous thromboembolism. British Journal of Nursing2006;15(18):980-6. [PMID: 17077768]">Autar 2006</a>; <a href="./references#CD012369-bbs2-0020" title="BoneuB . Prevention of venous thrombosis with antiplatelet agents [Prevention des thromboses veineuses par les agents antiplaquettaires]. Annales Francaises d'Anesthesie et de Reanimation1992;11(3):329. [PMID: 1503312]">Boneu 1992</a>; <a href="./references#CD012369-bbs2-0061" title="PaikinJS , WrightDS , EikelboomJW . Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. Blood Reviews2011;25(3):123-9. [PMID: 21354678]">Paikin 2011</a>; <a href="./references#CD012369-bbs2-0070" title="SchrorK . Aspirin and venous thromboses [Acetylsalicylsaure und venose Thrombosen]. Der Internist2015;56(1):84-90. [PMID: 25576252]">Schror 2015</a>; <a href="./references#CD012369-bbs2-0086" title="WatsonHG , CheeYL . Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. Blood Reviews2008;22(2):107-16. [PMID: 18226435]">Watson 2008</a>). <a href="./references#CD012369-bbs2-0016" title="AutarR . Evidence for the prevention of venous thromboembolism. British Journal of Nursing2006;15(18):980-6. [PMID: 17077768]">Autar 2006</a>, <a href="./references#CD012369-bbs2-0061" title="PaikinJS , WrightDS , EikelboomJW . Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. Blood Reviews2011;25(3):123-9. [PMID: 21354678]">Paikin 2011</a> and <a href="./references#CD012369-bbs2-0086" title="WatsonHG , CheeYL . Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. Blood Reviews2008;22(2):107-16. [PMID: 18226435]">Watson 2008</a> encompassed not only VTE or DVT. For instance, they also evaluated participants with arterial thromboembolism and myeloma. Nevertheless, concerning the VTE treatment and prevention, <a href="./references#CD012369-bbs2-0061" title="PaikinJS , WrightDS , EikelboomJW . Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. Blood Reviews2011;25(3):123-9. [PMID: 21354678]">Paikin 2011</a> and <a href="./references#CD012369-bbs2-0086" title="WatsonHG , CheeYL . Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. Blood Reviews2008;22(2):107-16. [PMID: 18226435]">Watson 2008</a> conclude that more RCTs were needed for better decision making. We have to note that both <a href="./references#CD012369-bbs2-0061" title="PaikinJS , WrightDS , EikelboomJW . Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. Blood Reviews2011;25(3):123-9. [PMID: 21354678]">Paikin 2011</a> and <a href="./references#CD012369-bbs2-0086" title="WatsonHG , CheeYL . Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. Blood Reviews2008;22(2):107-16. [PMID: 18226435]">Watson 2008</a> were published in 2011 and 2008, respectively, and two more recent RCTs that we considered had not been published yet (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>; <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>). However, in that time, four of our included RCTs had already been published (<a href="./references#CD012369-bbs2-0002" title="BelcaroG , ErrichiBM , De SimoneP . Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology1993;44(4):328-31. [PMID: 8457085]BelcaroG , LauroraG , CesaroneMR , De SanctisMT . Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. Angiology1993;44(9):695-9. [PMID: 8357095]">Indobufen 1993</a>; <a href="./references#CD012369-bbs2-0003" title="MoriauM , Lavenne-PardongeE , CrasbornL , vonFrenckellR , Col-DebeysC . The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research1995;78(6):469-82. [PMID: 15714749]">Moriau 1995</a>; <a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>), but those narrative reviews did not mention these studies in their reports. </p> <p>As another narrative review, <a href="./references#CD012369-bbs2-0070" title="SchrorK . Aspirin and venous thromboses [Acetylsalicylsaure und venose Thrombosen]. Der Internist2015;56(1):84-90. [PMID: 25576252]">Schror 2015</a> analysed the role of the utilisation of antiplatelet agents in primary and secondary prevention of VTE. They performed a narrative overview of <a href="./references#CD012369-bbs2-0076" title="SimesJ , BecattiniC , AgnelliG , EikelboomJW , KirbyAC , MisterR , et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation2014;130(13):1062-71. [PMID: 25156992]">Simes 2014</a> and, consequently, of two of our included RCTs (<a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a>; <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>). The conclusions did not differ from <a href="./references#CD012369-bbs2-0076" title="SimesJ , BecattiniC , AgnelliG , EikelboomJW , KirbyAC , MisterR , et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation2014;130(13):1062-71. [PMID: 25156992]">Simes 2014</a>. Similar to the <a href="./references#CD012369-bbs2-0061" title="PaikinJS , WrightDS , EikelboomJW . Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. Blood Reviews2011;25(3):123-9. [PMID: 21354678]">Paikin 2011</a> report, we could not directly compare our analysis with <a href="./references#CD012369-bbs2-0070" title="SchrorK . Aspirin and venous thromboses [Acetylsalicylsaure und venose Thrombosen]. Der Internist2015;56(1):84-90. [PMID: 25576252]">Schror 2015</a> because they evaluated only part of our included RCT and evaluated participants with VTE and not necessarily with confirmed DVT. </p> <p>Since the 1990s, there has been a hypothesis that antiplatelet agents may be beneficial for people with DVT (<a href="./references#CD012369-bbs2-0020" title="BoneuB . Prevention of venous thrombosis with antiplatelet agents [Prevention des thromboses veineuses par les agents antiplaquettaires]. Annales Francaises d'Anesthesie et de Reanimation1992;11(3):329. [PMID: 1503312]">Boneu 1992</a>). Our findings are in agreement with this hypothesis. Our certainty of evidence appears to suggest that antiplatelet agents could reduce the risk of recurrent VTE in the chronic phase of DVT with an equipoise between the benefits and harms, such as bleeding. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012369-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012369-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: 'Review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012369-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: 'Review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: 'Review authors' judgements about each risk of bias item for each included study." data-id="CD012369-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: 'Review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 1: Major bleeding" data-id="CD012369-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 1: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 2: Mortality" data-id="CD012369-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 2: Mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 3: Post‐thrombotic syndrome" data-id="CD012369-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 3: Post‐thrombotic syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 4: Post‐thrombotic syndrome" data-id="CD012369-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 4: Post‐thrombotic syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 5: Adverse events" data-id="CD012369-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 5: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 6: Adverse events" data-id="CD012369-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 6: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 1: Recurrent VTE" data-id="CD012369-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 1: Recurrent VTE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 2: Major bleeding" data-id="CD012369-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 2: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 3: Mortality" data-id="CD012369-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 3: Mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 4: Adverse events" data-id="CD012369-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP alone, Outcome 4: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo, Outcome 1: Recurrent VTE" data-id="CD012369-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo, Outcome 1: Recurrent VTE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo, Outcome 2: Major bleeding" data-id="CD012369-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo, Outcome 2: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo, Outcome 3: PE (fatal/nonfatal)" data-id="CD012369-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo, Outcome 3: PE (fatal/nonfatal) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo, Outcome 4: Mortality" data-id="CD012369-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo, Outcome 4: Mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo, Outcome 5: Adverse events" data-id="CD012369-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo, Outcome 5: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012369-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/urn:x-wiley:14651858:media:CD012369:CD012369-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo, Outcome 6: Duration of hospitalisation (days)" data-id="CD012369-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_t/tCD012369-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo, Outcome 6: Duration of hospitalisation (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/media/CDSR/CD012369/image_n/nCD012369-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012369-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Acute DVT ‐ antiplatelet agents plus BMP compared to BMP alone for the treatment of DVT</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antiplatelet agents plus BMP compared to BMP alone for the treatment of acute DVT</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring treatment for acute DVT<br/><b>Setting:</b> outpatient setting<br/><b>Intervention:</b> antiplatelet agents plus BMP<br/><b>Comparison:</b> BMP alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with BMP alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antiplatelet agents plus BMP</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b><br/>follow‐up: range 3 months to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported on a 6‐point scale used for clinical and ultrasonic assessment of efficacy, which included, among other outcomes, embolisation. Components of the score were not reported separately. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported no major bleeding.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pulmonary embolism</b><br/>follow‐up: range 3 months to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported on a 6‐point scale used for clinical and ultrasonic assessment of efficacy, which included, among other outcomes, embolisation. Components of the score were not reported separately. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> ‐ early and intermediate </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported no deaths.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Post‐thrombotic syndrome</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/>(0.61 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>580 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>151 less per 1000<br/>(226 less to 52 less) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.88<br/>(1.06 to 7.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>500<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 more per 1000<br/>(2 more to 272 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMP:</b> best medical practice; <b>CI:</b> confidence interval; <b>DVT:</b> deep venous thrombosis; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded a half level due to imprecision: fewer than 300 events were included in the analysis.<br/><sup>b</sup>Downgraded two levels due to study limitations. Despite the study described as blinded, the study did not have a control group with placebo, and intervention groups had differences in the number of tablets per day. Losses and exclusion were not mentioned. Some of the study's prespecified outcomes (such as embolisation) that were of interest for this review have not been reported. The full protocol was not available, only information in the study report. There was suspicion of pharmaceutical company support, although not clearly mentioned in the study report.<br/><sup>c</sup>Downgraded one level due to indirectness: there was no explanation about what was considered major bleeding.<br/><sup>d</sup>Downgraded a half level due to indirectness: the study authors did not utilise a validated method to assess post‐thrombotic syndrome. Only subjective vision of the participant. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Acute DVT ‐ antiplatelet agents plus BMP compared to BMP alone for the treatment of DVT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012369-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Chronic DVT ‐ antiplatelet agents plus BMP compared to BMP alone for the treatment of DVT</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antiplatelet agents plus BMP compared to BMP alone for the treatment of chronic DVT</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring treatment for chronic DVT<br/><b>Setting:</b> outpatient setting<br/><b>Intervention:</b> antiplatelet agents plus BMP<br/><b>Comparison:</b> BMP alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with BMP alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antiplatelet agents plus BMP</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b> ‐ early and intermediate </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.12<br/>(0.05 to 0.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>224<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Includes recurrent DVT only</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>293 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>258 less per 1000<br/>(278 less to 193 less) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>224<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported no major bleeding.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pulmonary embolism</b><br/>follow‐up: range 1 year to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>224<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported no pulmonary embolism.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> ‐ early and intermediate </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>224<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported no deaths.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Post‐thrombotic syndrome</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies measured this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>224<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study authors reported no adverse events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMP:</b> best medical practice; <b>CI:</b> confidence interval; <b>DVT:</b> deep venous thrombosis; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded a half level due to imprecision: fewer than 300 events were included in the analysis.<br/><sup>b</sup>Downgraded two levels due to study limitations: the control group did not have an oral treatment, not even placebo; participants and personnel were not blinded; authors reported that all included participants concluded the analysis but there were dropouts in all groups, without details provided; the full protocol was not available, only report information.<br/><sup>c</sup>Downgraded one level due to other considerations: there is suspicion of duplicate publication.<br/><sup>d</sup>Downgraded one level due to indirectness: no explanation as to what was considered major bleeding or if there was any. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Chronic DVT ‐ antiplatelet agents plus BMP compared to BMP alone for the treatment of DVT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012369-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Chronic DVT ‐ antiplatelet agents plus BMP compared to BMP plus placebo for the treatment of DVT</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antiplatelet agents plus BMP compared to BMP plus placebo for the treatment of chronic DVT</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring treatment for chronic DVT<br/><b>Setting:</b> outpatient setting<br/><b>Intervention:</b> antiplatelet agents plus BMP<br/><b>Comparison:</b> BMP plus placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with BMP plus placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antiplatelet agents plus BMP</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b> ‐ early, intermediate and long term </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.65 (0.43 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>901</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>206 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 less per 1000 (118 less to 8 less)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.29 to 3.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>583<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two studies did not assess this outcome (<a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>) and for one study the data were not available for our population of interest (<a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>). Only <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> had data for the analysis. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(12 less to 41 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pulmonary embolism</b> (fatal/non‐fatal) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.52<br/>(0.23 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>583<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two studies did not assess this outcome (<a href="./references#CD012369-bbs2-0004" title="SteeleP . Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet (London, England)1980;2(8208-8209):1328-9. [PMID: 6109150]">Steele 1980</a>; <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a>) and for one study the data were not available for our population of interest (<a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a>). Only <a href="./references#CD012369-bbs2-0001" title="ACTRN012605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/closed-trials/aspire/ (first received 1 May 2003). ACTRN12605000004662. ASPIRE. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. trialsearch.who.int/?trialid=ACTRN12605000004662 (first received 12 July 2005). ACTRN12605000004662. ASPIRE A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000004662 (first received 12 July 2005). BrightonT , EikelboomJ , MannK , MisterR , GallusA , Ockelford Petal. Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial. In: Late-Breaking Clinical Trial Abstracts. Circulation2012;126(23):2777. [DOI: 10.1161/CIR.0b013e318278c90d]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine2012;367(21):1979-87. [DOI: 10.1056/NEJMoa1210384]BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Protocol to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_protocol.pdf (accessed 7 December 2016). BrightonTA , EikelboomJW , MannK , MisterR , GallusA , OckelfordP , et al. Supplementary Appendix to 'Low-dose aspirin for preventing recurrent venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1210384/suppl_file/nejmoa1210384_appendix.pdf (accessed 15 August 2018). RobledoK . DVT subgroup data used in our trial [personal communication] [ASPIRE results]. Email to: CDQ Flumignan 12 December 2017. ">ASPIRE</a> had data for the analysis. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 less per 1000<br/>(45 less to 8 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> ‐ intermediate and long term </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/>(0.21 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>649<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 less per 1000<br/>(42 less to 3 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Post‐thrombotic syndrome</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies measured this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.57<br/>(0.34 to 7.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>621<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 more per 1000<br/>(49 less to 464 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMP:</b> best medical practice; <b>CI:</b> confidence interval; <b>DVT:</b> deep venous thrombosis; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded a half level due to imprecision: fewer than 300 events were included in the analysis.<br/><sup>b</sup>Downgraded a half level due to study limitations: in the <a href="./references#CD012369-bbs2-0006" title="BecattiniC , AgnelliG , PoggioR , EichingerS , BucheriniE , SilingardiM , et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. the WARFASA study. Blood2011;118(21):543. [online ISSN: 1528-0020]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism: correction. New England Journal of Medicine2012;367(16):1573. [DOI: 10.1056/NEJMx120070]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine2012;366(21):1959-67. [DOI: 10.1056/NEJMoa1114238]BecattiniC , AgnelliG , SchenoneA , EichingerS , BucheriniE , SilingardiM , et al. Supplementary appendix to 'Aspirin for preventing the recurrence of venous thromboembolism'. www.nejm.org/doi/suppl/10.1056/NEJMoa1114238/suppl_file/nejmoa1114238_appendix.pdf2012;(accessed 7 January 2017). NCT00222677. Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism in patients with idiopathic venous thromboembolism. The WARFASA Study. clinicaltrials.gov/ct2/show/NCT00222677 (first received 22 September 2005). ">WARFASA</a> protocol, we identified a change in primary and secondary outcomes during the study. <br/><sup>c</sup>Downgraded a half level due to study limitations: the <a href="./references#CD012369-bbs2-0005" title="SteeleP , Ellis J Jr, GentonE . Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. American Journal of Medicine1978;64(3):441-5. [PMID: 345802]">Sulfinpyrazone 1978</a> study included one group treated with warfarin, after randomisation. Moreover, the investigators used different anticoagulation treatments (warfarin or heparin) for some participants, and this was not sufficiently described. There are no details of numbers of anticoagulated participants in each group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Chronic DVT ‐ antiplatelet agents plus BMP compared to BMP plus placebo for the treatment of DVT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/full#CD012369-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012369-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Post‐thrombotic syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.61, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 piracetam ‐ 4 x 2.4 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.38, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 buflomedil ‐ 2 x 300 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.35, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 pentoxifylline ‐ 3 x 400 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.52, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 dipyridamole ‐ 2 x 200 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.72, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Post‐thrombotic syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.61, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 piracetam‐buflomedil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.42, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 pentoxifylline‐dipyridamole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.69, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.88 [1.06, 7.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 piracetam ‐ 4 x 2.4 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.12, 8.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 buflomedil ‐ 2 x 300 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.12, 8.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 pentoxifylline ‐ 3 x 400 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [0.48, 25.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 dipyridamole ‐ 2 x 200 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [0.85, 42.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.88 [1.06, 7.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 piracetam‐buflomedil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.22, 4.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 pentoxifylline‐dipyridamole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.75 [1.19, 19.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Acute DVT ‐ antiplatelet agents plus BMP versus BMP alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012369-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Chronic DVT ‐ antiplatelet agents plus BMP versus BMP alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Recurrent VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.05, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 without compression stockings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.03, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 with compression stockings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.03, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Chronic DVT ‐ antiplatelet agents plus BMP versus BMP alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012369-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Recurrent VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.43, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 ASA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.53, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 sulfinpyrazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 ASA plus dipyridamole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.02, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.29, 3.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 PE (fatal/nonfatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.23, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 all‐cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.21, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 VTE‐related</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 gastrointestinal adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.29, 8.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 respiratory adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.37, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 minor bleeds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.36, 10.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.4 total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.34, 7.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Duration of hospitalisation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐9.29, 5.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Chronic DVT ‐ antiplatelet agents plus BMP versus BMP plus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012369.pub2/references#CD012369-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012369.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012369-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012369-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012369-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012369-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012369-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD012369-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD012369-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD012369-note-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012369-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012369\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012369\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012369\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012369\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012369\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012369.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012369.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012369.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012369.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012369.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729498055"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012369.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729498059"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012369.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ede5b4a93bd65',t:'MTc0MDcyOTQ5OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 